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ABSTRACT 
Myung Soo Kim: Exosome Mediated Delivery of Paclitaxel for the Treatment of  
Multi-Drug Resistant Pulmonary Metastases 
(Under the direction of Elena Batrakova) 
 
Exosomes have recently come into focus as “natural nanoparticles” for use as drug delivery 
vehicles because they lack many drawbacks inherent to other nanoformulations. Many 
potentially useful chemotherapeutics possess undesirable attributes such as low solubility in 
aqueous solutions, immunogenicity, or inefficient accumulation in target cancer cells due to 
multidrug resistance (MDR) mechanisms. Our objective was to assess the feasibility of an 
exosome-based drug delivery platform for a potent chemotherapeutic agent, paclitaxel (PTX), 
to treat MDR cancers expressing the sigma receptor.  Herein, we developed and compared 
different methods of loading exosomes released by macrophages with PTX (exoPTX), 
vectorized to target the sigma receptor (exoPTX-AA), and characterized their size, stability, 
drug release, and in vitro antitumor efficacy. A reformation of exosomes upon sonication 
resulted in high loading efficiency, and sustained drug release.  Importantly, incorporation of 
PTX into exosomes increased cytotoxicity more than 50 times in drug resistant MDCKMDR1 
(Pgp+) cells. Furthermore, exoPTX and exoPTX-AA demonstrated significantly greater 
cytotoxicity against all cell lines tested, as compared to Taxol and PTX. The biodistribution of 
exoPTX and exoPTX-AA and the antitumor effects of exoPTX were further evaluated in a 
model of murine Lewis Lung Carcinoma pulmonary metastases. Our studies demonstrated 
nearly complete co-localization of airway-delivered exosomes and intravenously delivered 
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vectorized exosomes with cancer cells, and a potent anticancer effect of exoPTX in this mouse 
model. We conclude that exoPTX-AA holds significant potential for the delivery of various 
chemotherapeutics to treat drug resistant cancers.  
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CHAPTER 1. PREPARATION OF EXOSOMAL FORMULATION OF PACLITAXEL 
VECTORIZED TO SIGMA RECEPTOR12 
OVERVIEW  
The recently emerged field of nanotechnology holds great promise for developing drug 
delivery systems with targeting and controlled-release characteristics for cancer treatment; there 
have been many new advances and innovations made in this field during the past decade [1].   A 
large proportion of chemotherapeutic drugs have low aqueous solubility, consequently requiring 
the use of specialized delivery vehicles (e.g. micelle, liposome, polymeric nanoparticles, or other 
types of nanoparticles) for parenteral administration. These nanosized delivery vehicles are often 
complex and may be difficult to manufacture, cause unwanted side effects (such as the excipient 
Cremophor EL in the commercial formulation of PTX, Taxol), and/or are immunogenic.  The 
most common method of reducing the immunogenicity of nanoformulated drugs is to decorate 
the nanoparticle in a polyethylene glycol (PEG) corona, which reduces recognition by the 
reticuloendothelial system (RES) and aids in avoiding clearance.  
                                                          
1 Some of this text previously appeared in an article in the Journal of Controlled Release.  The original citation is as 
follows: Using exosomes, naturally-equipped nanocarriers, for drug delivery. Elena V. Batrakova, Myung Soo Kim. 
Review the “Americas” Special Issue of the J Contr. Rel. 2015 Aug 1. pii: S0168-3659(15)30042-0. doi: 
10.1016/j.jconrel.2015.07.030. 
2 Some of this text previously appeared in an article in the journal Nanomedicine.  The original citation is as 
follows: Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells. Myung Soo Kim, 
Matthew J. Haney, Yuling Zhao, Richa Gupta, Zhijian He, Natalia L. Klyachko, Aleksandr Piroyan, Marina Sokolsky, 
Alexander v. Kabanov, and Elena V. Batrakova. Nanomedicine, Nov 13. pii: S1549-9634(15)00202-6. doi: 
10.1016/j.nano.2015.10.012. PMID: 26586551 
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Exosomes are membrane-derived vesicles ~40-200 nm in diameter[1], they may be found 
in extracellular bodily fluids (e.g. urine, saliva, cerebrospinal fluid) and in conditioned cell 
culture media[2].  They are released by a variety of cell types and are formed when 
multivesicular bodies inside the cells fuse with the plasma membrane and release intraluminal 
vesicles into the extracellular microenvironment as exosomes[2, 3].  Exosomes naturally 
function as intracellular messengers, carrying RNA and proteins between the cells[4].  Recently, 
exosomes have begun to be explored for use as drug delivery vehicles for non-native therapeutics 
such as nucleic acids[5-10],  gene delivery using adeno-associated virus (AAV)[11-13], and 
small molecule drugs, such as curcumin[2, 14, 15], and doxorubicin[16].  It has been 
demonstrated that exosomes are able to deliver their intraluminal cargo into the cytosol of target 
cells[17].  In addition, allogenic exosomes may have an immune privileged status, which allows 
for decreased drug clearance compared to PEGylated nanoformulations. These unique features 
make exosomes an attractive option for use as a drug delivery vehicle for cancer treatment.    
Lung cancer is one of the most lethal forms of cancer and has a high rate of metastasis 
and recurrence; non-small cell lung cancer (NSCLC) is responsible for ~85% of all lung cancers, 
and prognosis of metastatic NSCLC is poor, with chemotherapy providing only minimal 
increases in survival rates, with a 5 year survival rate of <15% [18, 19].  It has been shown that a 
variety of cancer types, including NSCLC, overexpress the sigma receptor [20]. The sigma 
receptor is a popular target for nanoformulations treating various types of cancer, including lung 
cancer, and has been targeted for the delivery of drugs such as siRNA or doxorubicin [21-23]. 
Anisamide has been shown to have high affinity for the sigma receptor and has thus been utilized 
to target the sigma receptor[23].  Furthermore, Kooijmans et al. have recently shown that the 
introduction of polyethylene glycol (PEGylation) to exosomes results in stealth properties which 
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significantly increases their circulation time in mice, thus, PEGylation of exosomes may be 
utilized to increase the accumulation of exosomes at tumor sites or at sites of inflammation, 
which have enhanced vascular permeability and retention (EPR effect) [24]. 
Herein, we have developed a new nanoformulation consisting of exosomes loaded with 
PTX, a commonly used chemotherapeutic agent, and given stealth properties as well as 
vectorized to target the sigma receptor by the addition of DSPE-PEG-AA.  
Different methods of loading PTX into exosomes were assessed to identify the most 
efficient approach that provided the greatest loading capacity while minimizing any detrimental 
effects to the exosomal product.  In this study, we show that loading PTX into exosomes under 
mild sonication conditions followed by a 60 min. incubation period at 37°C increased drug 
solubility while maintaining exosomal membrane integrity and morphology, as well as allowing 
for the retention of critical exosomal proteins necessary for cell adhesion and uptake.   Next, the 
optimal formulation of exosomes vectorized to target the sigma receptor while maximizing drug 
loading capacity was determined.  First, an introduction to exosomes, methods of isolation, 
natural functions, and their use in drug delivery applications is given below. 
Introduction 
Biogenesis, Isolation, and Characterization of Exosomes 
The biogenesis, characterization, and functions of exosomes are exciting new fields of 
research that have triggered significant interest over the past three decades. Exosomes are 40 - 
100 nm sized extracellular plasma-membrane derived vesicles actively secreted by most cell 
types, in particular, cells of the immune system such as dendritic cells [25], macrophages [26], B 
cells [27], and T cells [28]; as well as mesenchymal stem cells [29], endothelial [30] and 
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epithelial cells [31]. Exosomes are also secreted by a variety of cancer cells [32]. They are 
defined by the size, surface proteins, and lipid composition. 
The unique properties of exosomes can be attributed to their biogenesis; they are initially 
produced by invagination of the endosomal membrane to create multivesicular bodies (MVB) 
(Figure 1.1).  
 
Figure 1.1. Schematic representation of different types of extracellular vesicles. 
 
In contrast, exosomes’ close relative, microvesicles, are greater in size (100 - 500 nm) 
and bud directly from the plasma membrane. Consequently, exosomes and microvesicles have 
endosomal (red) and plasma (green) membrane origin, respectively (Figure 1.1). Larger vesicles 
(500 - 1000 nm) are considered to be apoptotic vesicles (Figure 1.1). Many investigations, 
especially in the field of drug delivery, utilize both exosomes and microvesicles, defining them 
as extracellular vesicles, because a complete separation and purification of each type of vesicles 
is extremely laborious and difficult [33].  
Exosomes can be characterized by size, protein and lipid content. Different techniques 
were developed for the characterization of exosomes.  Among them are flow cytometry, western 
blotting, nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), mass 
spectrometry (MS) and several microscopy techniques [34].  The International Society for 
Extracellular Vesicles (ISEV) published a position paper in 2014, in which the characterization 
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of exosomes is recommended by the presence of exosome-associated surface markers, as well as 
the absence of proteins not associated with exosomes [35]. Exosomal surface markers include 
TSG101, Alix, flotillin 1, tetraspanins (CD9, CD63, CD81), integrins (ITG**), and cell adhesion 
molecules (CAM) [35]. Exosomes are highly enriched in cholesterol, sphingomyelin, and 
hexosylceramides at the expense of phosphatidylcholine and phosphatidylethanolamine [36]. The 
fatty acids in exosomes are mostly saturated or monounsaturated. Together with the high 
concentration of cholesterol, this may account for lateral segregation of these lipids into 
exosomes during their formation at MVB. Exosomes can be isolated from conditioned cell 
culture media or bodily fluids by differential centrifugation, filtration paired with centrifugation, 
immunoaffinity or size exclusion chromatography, or polymer-based precipitation. 
Differential Ultracentrifugation and Density Gradient Ultracentrifugation 
This method is considered the “gold standard” for isolating exosomes. It involves 
applying a centrifugal force to a solution containing exosomes, e.g. conditioned cell culture 
media or biological fluids.  First, a low speed centrifugation step (400 x g) is performed in order 
to remove cells and large cell debris.  The supernatant is then subjected to 10,000 – 20,000 x g to 
remove large debris and intact organelles.  Finally, the supernatant is again subjected to high 
speed centrifugation (100,000 - 150,000 x g) to pellet exosomes.  It is worth noting that the type, 
quantity, and quality of exosomes isolated by this method is sensitive to the g force, rotor type, 
angle of rotor sedimentation, radius of centrifugal force, pelleting efficiency, and solution 
viscosity. One issue with differential ultracentrifugation is that it sediments exosomes as well as 
other vesicles, proteins, and/or protein-RNA aggregates.  By including a sucrose density 
gradient, contaminants with densities different than exosomes may be separated from exosomes, 
allowing for recovery of a theoretically more pure fraction. Gradient centrifugation requires 
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extensive (62 – 90 h) centrifugation time [37], but provides a more uncontaminated exosome 
isolate than ultracentrifugation alone. 
A fast and efficient method of exosome isolation was reported in [38]. Exosomes from 
monocyte-derived dendritic cells were rapidly purified (e.g. 4–6 h of a 2–3 L culture) based on 
their unique size and density. Ultrafiltration of the clarified supernatant through a 500-kDa 
membrane and ultracentrifugation into a 30% sucrose/deuterium oxide (D2O) (98%) cushion 
(density 1.210 g/cm3) reduced the volume and protein concentration approximately 200- and 
1000-fold, respectively. The percentage recovery of exosomes ranged from 40% to 50% based 
on the exosome MHC class II concentration of the starting clarified supernatant [38]. While 
differential centrifugation has the potential for higher exosome yields, this method is subject to 
operator-dependent variability [38]. 
Immunoaffinity Chromatography 
Immunoaffinity chromatography is a process in which antibodies, covalently attached to 
beads, filters, or other matrices, bind to specific surface proteins or antigens on the target particle 
and non-target particles remain unbound.  The unbound fraction is discarded, and the desired 
bound fraction may be collected by washing the stationary phase, typically with a low pH buffer.  
For the isolation of exosomes, antibodies to exosomal surface markers such as TSG101 or 
tetraspanins are used (exosomal surface markers will be discussed further below).  Tauro et al. 
showed that immunoaffinity chromatography is a more efficient method for isolating exosomes 
as compared to differential ultracentrifugation and density gradient ultracentrifugation [39]. 
However, because this method of exosomes isolation depends on antibody recognition of 
exosomal proteins, only a subset of all extracellular vesicles (those expressing the antibody-
recognized protein) can be captured. 
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Size Exclusion Chromatography 
Size exclusion chromatography (SEC) is a method wherein a solution consisting of a 
heterogeneous population of differently sized components is separated based on their size.  A 
column containing heteroporous beads is used in SEC; components with a smaller hydrodynamic 
radius are able to pass through the many small pores, akin to a maze, resulting in a longer time to 
elute.  Components with a larger hydrodynamic radius are unable to penetrate through as many 
pores, and thus elute earlier from the column.  In this manner, exosomes may be separated from 
other vesicles and contaminants of different sizes.  The advantages of SEC are that it preserves 
the integrity and biological activity of exosomes and other molecules being separated; because 
SEC is typically performed using gravity flow, vesicle structure and integrity remains intact.  
Furthermore, SEC has excellent reproducibility and sensitivity.  However, because SEC uses 
gravity flow, it requires a long run time which limits its scalability for high-throughput 
applications. 
Polymer Precipitation 
Polymer precipitation has been used to isolate viruses and other macromolecules for more 
than 50 years, typically by use of a solution containing polyethylene glycol (PEG).  The most 
commonly used commercial polymer precipitation-based product for exosome isolation is 
ExoQuick-TC™ from System Biosciences.  Typically, to isolate exosomes, a precipitation 
solution consisting of PEG with a molecular weight of 8,000 Da is used.  This precipitation 
solution is combined with biofluid containing exosomes and is incubated overnight at 40C.  The 
mixture is then centrifuged at low speed to form a pellet containing exosomes.   The product is 
relatively easy to use, and does not require specialized equipment or a lengthy run time.  
However, it has been shown that this method co-precipitates non-vesicular contaminants such as 
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lipoproteins, as well as polymer material [40].  These issues may be addressed by pre- and post-
isolation steps.  Pre-isolation involves the removal of subcellular particles such as lipoproteins.  
Post-isolation involves removal of the polymer, typically by using a Sephadex G-25 column 
[37]. 
Natural Functions of Exosomes and Their Intrinsic Biological Activity 
Exosomes play a significant and diverse role in intercellular communication that is an 
essential process for the development and function of multicellular organisms. These 
extracellular vesicles were initially thought to be a mechanism for removing unneeded 
membrane proteins from reticulocytes. Recent studies have shown that they are specialized in 
long-distance intercellular communications  [41, 42] facilitating transfer of proteins [43, 44], and 
functional mRNAs and microRNAs for subsequent protein expression in target cells [45, 46]. 
This mechanism of secretion, signaling and communication is a highly efficient, robust, and 
economic manner of exchanging information between cells. Thus, exosomes themselves exert 
unique biological activity, even without any loaded drug that may be used for therapeutic 
purposes. 
Immune Regulation by Exosomes 
Tumor cells are poorly immunogenic and this has hampered the development of effective 
cancer immunotherapy. By transporting ligands and receptors, exosomes can trigger an anti-
tumor response by presenting tumor antigens to immune cells. Initially, tumor-derived exosomes 
that carry antigens have been suggested as a source of specific stimulus for the immune response 
against tumors [47]. These exosomes were shown to induce anti-tumor responses more 
efficiently than irradiated tumor cells, apoptotic bodies, or tumor cell lysates. For example, 
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mouse B lymphoma cells were reported to release exosomes that carry a number of heat shock 
proteins (HSP) that induced significant antitumor immune responses in T cells [48].  
Later, it was demonstrated that tumor-derived exosomes can also possess 
immunosuppressive properties [49], promote oncogenesis, metastasis [50, 51], and drug 
resistance development [52-54]. Therefore, the attention was turned to the exosomes released by 
activated antigen presenting cells (APCs), such as dendritic cells (DCs), macrophages, T 
lymphocytes, and B cells. The presence of MHC class I and II, as well as T cell co-stimulatory 
molecules, on the surface of these exosomes could be an important mechanism of antigen 
presentation [55]. Furthermore, the immune response cells primed with antigens can package 
cellular components from cancer cells in exosomes that then promote immune responses [56-62]. 
In particular, exosomes secreted by DCs that were primed with acid-eluted tumor peptides were 
reported to eradicate established tumors in mice [56]. According to another study, DCs-secreted 
exosomes incubated with human breast adenocarcinoma cells (SK-BR-3) were able to induce 
tumor-sensitized T cells to secrete high levels of Interferon-γ (IFN-γ) [57]. Qazi et al. [58] 
reported a significant anti-cancer activity of exosomes secreted by DCs that were exposed to 
chicken egg ovalbumin (OVA). These exosomes elicited specific transgenic T cell proliferation 
in vitro. Interestingly, two different methods of OVA loading into exosomes were compared: 
OVA peptide that was directly loaded into exosomes (Pep-Exo), or exosomes released from 
OVA-pulsed DCs (OVA-Exo). Pep-Exo formulation was more efficient in specific transgenic T 
cell proliferation in vitro. However, only exosomes released from OVA-pulsed DCs were 
efficient in vivo, highlighting the importance of formulation strategies in some cases [58]. 
Noteworthy, DCs-derived exosomes may also exert undesirable effects, such as triggering the 
anti-donor T cell response that causes allograft rejection [63].  
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Along with the improving immune responses, exosomes released from T cells were 
shown to destroy tumor stroma, and prevent tumor invasion and metastases. In addition, cross-
talk between T lymphocytes and endothelial cells through exosomes was reported [59]. Thus, T 
cell-derived exosomes were shown to modulate endothelial cell responses to vascular endothelial 
growth factor (VEGF) and alter tube formation and gene expression in target endothelial cells. 
Mechanistic studies revealed that overexpression of thrombospondin-1 and its receptor CD47 on 
exosomes derived from T cells allowed targeted and facilitated internalization of these 
extracellular vesicles into endothelial cells. CD47 transferred to the tumor vasculature by 
exosomes modulated tumor angiogenesis and inhibited pro-angiogenic signaling in endothelial 
cells [59]. Noteworthy, the induction of immune responses may be mediated not only by the 
bioactive lipids and proteins present in exosomes, but also by exosome-associated RNAs [60]. 
Contained inside exosomes, microRNAs (miRNAs) play a key role in mediating biological 
functions due to their prominent role in gene regulation. Thus, Aucher at al. [61] reported that 
human macrophages can transfer miRNAs to hepato-carcinoma cells and functionally inhibit 
proliferation of these cancerous cells. The transport of these miRNA was associated with 
extracellular vesicles.  
Regarding infectious diseases, a succesful immunisation against difteria and Leishmania 
infections was achived by use of DC-derived exosomes that were exposed to difteria toxin [64] 
or Leishmania major [65] antigens, respectively. Furthermore, exosomes that were found in 
human breast milk can boost the immune response and alter the T cell balance toward a 
regulatory phenotype [66, 67]. This mechanism may be crucial for the development of the 
infants’ immune system. Thus, exosomes are potent immune regulators, and may be utilized for 
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the design of vaccine adjuvants and therapeutic intervention strategies to modulate immune 
responses.  
Protective and Regenerative Effects of Exosomes 
Exosomes play a vital role in regulating a broad range of physiological and pathological 
cellular processes [68] that may be utilized for therapeutic purposes. Mesenchymal stem cells 
(MSCs) derived from bone marrow, adipose tissue, cord blood, and other origins have recently 
received much attention as potential therapeutic agents with regenerative properties [69-76]. It 
was reported that MSCs-derived exosomes produced significant cardio-protective paracrine 
effects against myocardial ischemia/reperfusion injury in pig and mouse models [69, 70]. These 
exosomes may also be beneficial in pulmonary hypertension (HP). HP is a kind of malignant 
pulmonary vascular disease characterized by an increase in pulmonary artery pressure, which 
may lead to heart failure and even death. MSCs-derived exosomes directly suppressed early 
pulmonary inflammation and vascular remodeling [71] through the suppression of hyper-
proliferative pathways, including signal transducer and activator of transcription 3 (STAT3)-
mediated signaling.  
Exosomes secreted from cardiosphere-derived cells (CDCs) were shown to produce a 
range of diverse cardio-protective effects, including anti-inflammatory, anti-oxidative, anti-
apoptotic, anti-fibrotic, and cardiomyogenic effects [76, 77].  CDCs-released exosomes stimulate 
angiogenesis, promote cardiomyocyte proliferation, and decreased programmed cell death in 
vitro. The regenerative capacity of these exosomes was demonstrated in a model of chronic 
myocardial infarction (MI) in rats [78]. These effects were attributed to the ability of exosomes 
to reduce collagen deposition and exert anti-fibrotic efficacy via paracrine mechanisms [79]. In 
addition, CDCs-released exosomes improved cardiac function, imparted structural benefits, and 
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increased viable mass after MI. The observed therapeutic effects were associated with 
normalized oxygen consumption, induced ATP production, and preserved mitochondrial 
integrity.   
Exosomes derived from endothelial cells are a promising strategy to combat 
atherosclerosis [80]. Atherosclerosis, the underlying cause of myocardial infarction and stroke, 
occurs predominantly in predisposed spots in the large arteries. Systemic administration of 
exosomes released from human umbilical vein endothelial cells  (HUVECs) reduced 
atherosclerotic lesions in mice fed a high-fat diet. It is known that shear stress and its central 
transcriptional regulator KLF2 elicit atheroprotective properties to the endothelium by regulating 
the expression of atheroprotective genes. Exosomes secreted by shear-stress-stimulated HUVECs 
were enriched in multiple miRNAs, prominently miR-143 and miR-145.  HUVECs-released 
exosomes transported these miRNAs to smooth muscle cell (SMCs) which resulted in controlled 
target gene expression and reduction of atherosclerotic lesion formation in the mouse aorta [80].  
MSCs-derived exosomes were shown to have neuroprotective effects in stroke. The 
release, as well as the content, of the MSC-generated exosomes can be modified by 
environmental conditions. Thus, stroke induces changes in the miRNA profile of MSCs-released 
exosomes [81, 82], especially in miRNAs that actively participate in the recovery process after 
stroke [83]. MSCs-derived exosomes transferred their therapeutic factors to recipient cells, and 
altered gene expression and thereby promoted neurite growth in rat primary neurons [73]. 
Hepatic regeneration was shown by use of MSC-derived exosomes in drug-induced liver injury 
models [84]. The higher survival rate was associated with up-regulation of the priming-phase 
genes during liver regeneration, which subsequently led to higher expression of proliferation 
proteins (PCNA and cyclin D1) in the exosomes-treated group. Therapeutic effects of exosomes 
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derived from human adipose tissue-derived MSCs were also reported for treatment of Alzheimer 
disease (AD) [72].  It was demonstrated that these exosomes carry enzymatically active 
neprilysin (NEP), the most important enzyme that degrades β-amyloid (Aβ) peptide plugs in the 
brain. MSCs-derived exosomes decreased both intracellular and extracellular Aβ levels in a 
neuroblastoma cell line N2A in vitro. Finally, Ju et al. showed protective effects of exosome-like 
nanoparticles isolated from crushed grapes [85]. Multivesicular bodies have been also identified 
in plants, and leaderless secreted proteins can be released in vesicles, as described recently [86]. 
Ju and colleagues observed that oral administration of exosome-like nanoparticles from grapes to 
mice led to the significant proliferation of the intestinal epithelium.  
Using Exosomal Carriers for Therapeutics 
Drug Loading into Exosomes 
 
Figure 1.2 Different approaches for drug loading into exosomes. 
These are several distinct approaches for loading of exosomal carriers with drugs (Figure 
1.2): (A) loading naïve exosomes isolated from parental cells ex vitro; (B) loading parental cells 
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with a drug, which is then released in exosomes; and finally, (C) transfecting/infecting parental 
cells with DNA encoding therapeutically active compounds, which are then released in 
exosomes.  Each of the approaches has its advantages and limitations, and may be dictated by the 
type of therapeutic agent. 
Regarding ex vitro loading of naïve exosomes (Figure 1.2, Path A), different methods 
for drug incorporation were suggested.  In most cases, lipophilic small molecules were passively 
loaded into exosomes during co-incubation with exosomes [87-93]. Thus, low molecular 
antioxidant, curcumin [89, 90], anticancer agents, Doxorubicin (Dox) [92, 93] and Paclitaxel 
(PTX) [94], and a model drug Rhodamine 123 [94] were loaded into exosomes by the incubation 
at room temperature (RT). The drug loading upon this loading procedure determined by HPLC 
varied from 7.2% for PTX to 11. 7% for Dox.  
Exosomes naturally deliver mRNA, miRNA, various noncoding RNA, mitochondrial 
DNA, and genomic DNA [95, 96]. Therefore, they were suggested as carriers for nucleic acids 
transfer. Similar to the incorporation of genetic material into living cells, electroporation of 
purified exosomes was proposed for loading of exogenous RNA [5, 97-100].  Alvarez-Erviti et 
al. pioneered this method, electroporating siRNA into DC-derived exosomes [5]. The same 
method was used to load exosomes with miRNA to epidermal growth factor receptor (EGFR)-
expressing breast cancer cells [101]. About 3,000 miRNA molecules were loaded per exosome. 
It should be taken into consideration that electroporation of extracellular vesicles with siRNA 
may be accompanied by extensive siRNA aggregate formation, which may cause overestimation 
of the amount of siRNA actually loaded into exosomes [102]. The authors suggested that 
electroporation is far less efficient than previously reported, and highlighted the necessity for 
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alternative methods to prepare siRNA-loaded exosomes. Exosomes are known to carry a nega-
tive surface charge, hence precluding electrostatic siRNA complexation. Pre-complexation of 
siRNA via cationic liposomes followed by fusion with isolated exosomes has been suggested for 
their loading with siRNA by Wahlgren et al. [103]. Furthermore, elevated temperature (370C) 
was may be used for improved siRNA loading into exosomes [104]. 
Exosomes are also known to be nature’s way of delivering different proteins [105]. We 
suggested harnessing this mechanism for the delivery of a potent antioxidant, catalase, in 
exosomes [106]. Catalase is a large protein (MW 240 kDa that is susceptible to deactivation and 
rapid degradation, therefore the efficient incorporation of catalase in exosomes would be 
beneficial, but is not a simple task. We evaluated several loading methods. The amount of 
catalase loaded into exosomes increased as follows: incubation at RT < freeze/thaw cycles < 
sonication  extrusion  permeabilization with saponin. The highest loading capacity for catalase 
in exosomes was in the range of 20% - 26%. We hypothesized that the extensive reformation and 
reshaping of exosomes upon sonication and extrusion enabled catalase diffusion across relatively 
tight and highly structured lipid bilayers that resulted in the high loading efficiency of exosomal 
carriers. Furthermore, saponin treatment also increased catalase loading into exosomes. Saponin 
is an efficient permeabilization agent for cellular plasma membranes [107]. It is likely that, 
similar to whole cells, saponin can selectively remove membrane-bound cholesterol on 
exosomes, creating holes/pores in the exosomal lipid bilayers and thereby promoting catalase 
incorporation. Notably, aside from proteins, these methods for loading into exosomes can be 
applied to other therapeutic and imaging agents, in particular, gold nanoparticles [106]. 
As a second approach, parental cells can be loaded with exogenous compounds which 
then are released into the conditioned media inside exosomes (Figure 1.2, Path B). Thus, MSCs-
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secreted exosomes were loaded with PTX by incubating the parental cells with the drug [108]. It 
was reported that the murine SR4987 cells that were used as MSCs model produced a significant 
amount of PTX-loaded exosomes as demonstrated by HPLC [108]. A similar result was reported 
for HepG2 cells that were incubated with different anticancer agents: PTX, Etoposide, 
Carboplatin, Irinotecan, Epirubicin, and Mitoxantrone [109]. Exosomes released from drug-
treated HepG2 cells demonstrated strong anti-proliferative activity on the human pancreatic cell 
line CFPAC-1 and induced immunogenicity and HSPs-specific NK cell responses [109]. In 
another study, the breakdown of parental cells (monocytes /macrophages) loaded with anticancer 
agents, Dox, Gentamicin, 5-Fluoracil, or Carboplatin with subsequent isolation of exosome-like 
nanoparticles was also suggested [91]. An elegant approach to pack hydrophobic 
photosensitizers into exosomes was developed by professor Ji-Ho Park and his team in South 
Korea [110]. The researchers treated parental cells with synthetic membrane fusogenic liposomes 
loaded with hydrophobic therapeutics. The drug-loaded liposomes were efficiently incorporated 
into the membrane of exosomes in the parental cells and were consequently secreted from the 
cells.  
We developed a new approach of loading parental cells (monocytes/macrophages) with 
catalase followed by isolation of drug-loaded exosomes from conditioned media (Figure 1.2, 
Path B) [106, 111]. To preserve the therapeutic protein against degradation in host cells and 
increase loading capacity, catalase was incorporated into a polymer-based nanocontainer before 
loading. Importantly, the formulation design of this polymer-based nanocontainer was different 
from the common approach, where a drug nanoformulation is prepared for systemic 
administration. Protective nanoparticles are typically size-restricted to avoid entrapment in MPS, 
focusing on small size nanoparticles with a PEG corona (to perpetuate a stealth effect). In 
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contrast, the best nanoformulation for loading into parental cells had a relatively large size (c.a. 
200 nm) that resulted in improved accumulation in parental cells, and drug reshuffling into 
exosomes. The cross-linking of polymer-based nanoparticles with an excess of a non-
biodegradable linker ensured low cytotoxicity of nanoformulation and efficient catalase 
protection in the parental cells [106, 112].  
Finally, isolation of drug-loaded exosomes secreted from genetically-modified parental 
cells has been suggested as a third way of manufacturing exosome-based formulations (Figure 1.2, 
Path C) [33, 87, 111, 113]. As an example, OVA was loaded into exosomes when parental cells 
were transfected with OVAC1C2 fusion cDNA consisting of: (i) the cargo-encoding gene 
(OVA), and (ii) the gene encoding a protein known to localize to exosomes (C1C2) [113]. Our 
lab developed a new drug delivery system for different therapeutic proteins, where macrophages 
were transfected with plasmid DNA (pDNA) encoding therapeutic proteins, catalase [114], or glial 
cell-line derived neurotropic factor (GDNF) [111] to treat neurodegenerative disorders.  An 
interesting approach for incorporation of adeno-associated virus (AAV) capsids into extracellular 
vesicles to diminish their immunogenicity and improve gene delivery was suggested by [115]. It 
was reported that during production, a fraction of released AAV vectors were associated with 
exosomes, termed vexosomes (vector-exosomes), which outperformed conventionally purified 
AAV vectors in transduction efficiency in vitro.  
Therapeutic Effects of Drug-Loaded Exosomes 
Since exosomal carriers can provide advantages of both cell-based drug delivery and 
nanotechnology, interest in using exosomes for therapeutic approaches has exploded in recent 
years. Similar to viruses, these remarkable carriers are capable of traveling from one cell to 
another, easily passing their contents across the cell membrane due to their unique 
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characteristics, and delivering their cargo in a biologically active form. Noteworthy, exosomes 
possess an intrinsic ability to cross biological barriers, including the most difficult to penetrate, 
blood brain barrier (BBB). 
Exosomes have been exploited as drug delivery vehicles for low molecular drugs in 
several investigations [89-94, 108, 110]. In one of the first reports, exosomes loaded with an 
anti-inflammatory small molecule compound, curcumin, were shown to protect mice from 
lipopolysaccharides-induced brain inflammation [89, 90]. The incorporation of curcumin in 
exosomes improved its solubility, increased circulation time, preserved drug therapeutic activity, 
and improved brain delivery. In another study, exosomes loaded with different 
chemotherapeutics, Dox or PTX, were shown to traffic to tumor tissues and reduce tumor growth 
in mice without the adverse effects observed with the equipotent free drug [91-93]. Notable, the 
therapeutic effects of Dox-loaded exosomes were greater than the commercially available Dox-
loaded liposomes, Doxil; the liposomal formulation was inefficient in reducing tumor growth in 
this model [91]. Pascucci et al. observed that PTX-treated MSCs mediated strong anti-
tumorigenic effects because of their capacity to take up the drug and later release it in 
extracellular vesicles [108]. In this study, PTX-treated exosomes induced a dose-dependent 
inhibition of CFPAC-1 (human pancreatic adenocarcinoma) cell proliferation, as well as 50% 
inhibition of tumor growth. Next, exosomes loaded with hydrophobic photosensitizers exhibited 
superior phototherapeutic effects compared with the polymer-based synthetic nanoparticles 
[110]. This strategy allowed hydrophobic photosensitizers to significantly penetrate both 
spheroids and in vivo tumors, thereby enhancing the therapeutic efficacy. Finally, exosomes 
derived from brain endothelial cell line, bEND.3, were loaded with anticancer drugs and used for 
systemic delivery across the BBB to treat gliomas [94]. 
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Another therapeutic avenue involves the use of exosomes to deliver exogenous siRNA [5, 
97-100, 103, 116-118]. Wahlgren et al. reported the efficient silencing of the target MAPK gene 
in monocytes and lymphocytes using peripheral blood exosomes with incorporated exogenous 
siRNAs [103]. In another investigation, Shtam et al. introduced two different exogenous siRNAs 
against RAD51 and RAD52 into exosomes derived from HeLa cells [116]. In particular, the 
exosome-delivered siRNA against RAD51 was functional and caused the massive reproductive 
cell death of recipient cancer cells. The effect of exosome-siRNA gene silencing has also been 
validated in [117, 118]. As an example, extracellular vesicles were used to transport siRNA 
targeted to miR-150 [118]. miR150 is an oncomir due to its promotional effect on VEGF. It was 
demonstrated that the neutralization of miR-150 down-regulated VEGF levels in mice and 
attenuated angiogenesis.  
The genetic modification of donor cells was also used for targeting exosomes to the 
disease site. As an example, targeting of exosomes to the brain was achieved by engineering the 
parental DCs to express lysosomal-associated membrane protein 2 (Lamp2b), fused to the 
neuron-specific peptide derived from rabies virus glycoprotein (RVG) [5]. Systemically 
administered RVG-targeted exosomes delivered glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) siRNA specifically to neurons, microglia, oligodendrocytes in the brain, resulting in 
specific gene knockdown. The therapeutic potential of exosome-mediated siRNA delivery was 
demonstrated by the strong mRNA (60%) and protein (62%) knockdown of BACE1, a 
therapeutic target in Alzheimer's disease, in wild-type mice [5].  
Exosomes released from macrophages genetically-modified to express antioxidant, 
catalase, and glial cells-derived neurotrophic factor (GDNF) were suggested for the treatment of 
Parkinson’s disease (PD) [111, 114]. Mechanistic studies revealed that exosomes secreted from 
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genetically-modified parental cells contained the encoded therapeutic protein, as well as its 
genetic material (DNA and mRNA), and NF-b, a transcription factor involved in the encoded 
gene expression [114]. Drug-loaded exosomes were able to efficiently transfer their contents to 
contiguous neurons resulting in de novo protein synthesis in target cells. Transfected brain 
tissues showed month-long expression of the encoded protein and prolonged attenuation of 
neuroinflammation (over 40 days) in mice with neuroinflammation [114]. Overall, these reports 
indicate that exosomes may function as exceptional gene delivery vectors that are safe, efficient, 
organ/cell-specific, and non-immunogenic. However, significant efforts are required to develop 
these therapies for clinical use. 
Using Exosomal Drug Formulations in the Clinic 
In clinical settings, several approaches may be applied to introduce exosome-based drug 
delivery systems.  First, leukocytes harvested from peripheral blood by apheresis may be 
propagated and cultured, differentiated to specific cell types if necessary, and then exosomal 
carriers can be loaded with a therapeutic agent and re-administered back into the patient (Figure 
1.3). One of the major challenges in developing this approach is whether the production of 
exosomes could be scalable or reproducible [119]. Indeed, the exosome yield per cell will impact 
the final production cost as well as clinical applications. In this respect, the choice of parental 
cells is critical. For example, MSCs are known to produce large amounts of exosomes, 
suggesting that these cells may be efficient for exosome production in a clinically applicable 
scale [120]. Next, extended culturing of donor cells may considerably increase exosomal 
production. For example, culturing DCs for extended time period [38], or at low pH [121] 
increased the exosomal production of exosomes 5-10 fold. In another study, the breakdown of 
parental cells (monocytes/macrophages) loaded with anticancer agents, and isolation of 
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exosome-like nanoparticles allowed a 100-fold higher production yield of the drug carriers [91]. 
Finally, specifically designed bioreactors that resemble bioreactors for tissue engineering [122] 
can be utilized for exosomes scale-up.  Notably, exosomes can be concentrated, lyophilized, and 
reconstituted in aqueous solutions, as was reported in [106]. 
 
Figure 1.3. The flow of the production and delivery of exosomal drug formulations to the patient. 
 
As an alternative approach, MSCs may be harvested from bone marrow, propagated in 
culture to obtain specific cell types, or even subtypes, and then exosomes may be loaded with a 
therapeutic agent. Although this approach would require a more invasive procedure, a significant 
amount of as well as storage of well-characterized exosomal carriers would be possible [123]. 
Furthermore, large scale production of therapeutically efficacious exosomes can be achieved 
through the immortalization of donor cells; for example, mesenchymal stem cells can be 
transfected by lentivirus carrying a MYC gene as reported in [124]. MYC is a regulator gene that 
codes for a transcription factor that plays a role in cell cycle progression. The transfection allows 
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for obtaining of immortalized cells, but does not alter the fundamental characteristics of these 
MSCs [124]. In this case, a library of various types of exosomal carriers for different drug 
formulations could be developed in the future, and stored in stock for emergency situations. 
Finally, exosomes may be isolated from other sources (bovine milk, crashed grapes, etc.), 
purified, loaded with a drug and used for oral or intranasal administration. 
In fact, exosomes have already been approved for use in clinical trials, and our 
experience with exosome-based therapies in humans is rapidly expanding [125]. In particular, 
exosomes were purified from monocyte cultures from 15 patients with advanced metastatic 
melanoma. The good manufacturing procedures (GMP) process allowed harvesting about 5 x 
1014 exosomal MHC class II carriers. Then, the exosomes were loaded with melanoma antigen ex 
vitro, and administered in an autologous fashion in an attempt to promote anti-melanoma 
immunity via therapeutic vaccination.  It was reported that patients well-tolerated repeated 
administration of autologous exosomes for up to 21 months [126]. In a similar trial, non-small-
cell-carcinoma lung cancer patients were injected with autologous exosomes weekly for 4 weeks, 
and similar low level immune responses were observed [127]. In another trial for the treatment of 
NSCLC, patients were given dendritic cell derived exosomes bearing IL-15Ra and NKG2D and 
also given cyclophosphamide after platinum-based chemotherapy.  Finally, ascites-derived 
exosomes in combination with the granulocyte-macrophage colony-stimulating factor (GM-CSF) 
were utilized in the immunotherapy of colorectal cancer (CRC). A total of 40 patients with 
advanced CRC were enrolled in this clinical trial and received from 100 to 500 µg of exosomal 
formulations [128]. The exosomal-based therapies were safe, feasible, and efficient in induction 
of antigen-specific T lymphocyte response, however, several technical obstacles remain which 
must be overcome.  
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MATERIALS AND METHODS 
Reagents 
Paclitaxel (PTX) was purchased from LC Laboratories (Woburn, MA, USA).  The stock 
solution was prepared in ethanol (EtOH) at a concentration of 10 mg/mL.  Aliquots were stored 
at -20°C.  Working solutions of PTX were prepared fresh according to experimental design by 
serial dilution in EtOH. A fluorescent dye, 2-decanoyl-1-(O-(11-(4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-propionyl)amino)undecyl)-sn-glycero-3-phosphocholine 
(BODIPY-PC) was purchased from Molecular Probes. Cell culture medium and fetal bovine 
serum (FBS) were purchased from Gibco Life Technologies, Inc. (Grand Island, NY, USA). 
Culture flasks and dishes were purchased from Corning Inc. (Corning, NY, USA).  ExoQuick-
TC™ Exosome Precipitation Solution was obtained from System Biosciences (Mountain View, 
CA, USA). 
Cells 
RAW 264.7 macrophages (purchased from ATCC, Manassas, VA, USA) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) high glucose (Gibco, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 1% 
penicillin and streptomycin at 37°C and 5% CO2.   
Exosome Isolation 
For all studies, exosome-depleted media was prepared by ultracentrifugation of fetal 
bovine serum (FBS) at 120,000 x g for 110 min to remove all vesicular content prior to addition 
to media with 1% penicillin and streptomycin.  Exosomes were harvested from the supernatants 
of RAW 264.7 cells cultured in exosome-depleted media using the ExoQuick-TC™ Kit (System 
BioSciences; Mountain View, CA, USA).  Briefly, > 90% confluent RAW 264.7 cells were 
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cultured in exosome-depleted media for 2 days at 37°C and 5% CO2.  50 mL conditioned cell 
culture media were centrifuged at 300 x g for 10 min (Thermo CL-10 centrifuge with O-G26/1 
rotor, Thermo Fisher Scientific, Waltham, MA, USA) in order to remove cells and cellular 
debris.  The supernatant was then taken, filtered with a .22 µm PES filter, and ExoQuick-TC™ 
Exosome Precipitation Solution (System Biosciences, Mountain View, CA, USA) was added to 
the filtered supernatant and the mixture was vortexed and incubated overnight at 4°C.  After 
overnight incubation, the mixture was vortexed again and subsequently centrifuged at 1500 x g 
for 30 min. and 5 min. to pellet exosomes.  The supernatant was discarded and the exosome 
pellet was resuspended in PBS.  Freshly-prepared exosomes or exosomes stored at -20°C were 
used for all experiments. 
Drug Loading into Exosomes 
For PTX loading into exosomes, purified exosomes (~1011 exosomes) were first mixed 
with PTX in 1 mL PBS.  First, PTX was dissolved in ethanol (EtOH, 10 mg/mL drug in EtOH 
stock solution) and added to 1 mL exosomes. Different methods of drug loading were 
investigated: incubation at room temperature (RT), electroporation, and sonication. For the 
incubation method, the mixture was incubated at 37°C for 1 hour with shaking.  For the 
electroporation method, exosomes were mixed with PTX and added to a chilled 4 mm 
electroporation cuvette.  The mixture was then electroporated using an Eppendorf Eporator 
(Eppendorf AG, Hamburg, Germany) at 1000 kV for 5 ms, and then incubated at 37°C for 30 
min to allow for recovery of the exosomal membrane.  For the sonication method, the PTX-
exosome mixture was sonicated using a Model 505 Sonic Dismembrator with 0.25” tip (Thermo 
Fisher Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s on/off for 
three minutes with a two minute cooling period between each cycle.  After sonication, PTX-
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loaded exosomes (exoPTX) solution was incubated at 37°C for 60 min to allow for recovery of 
the exosomal membrane.   
Excess free PTX was separated from exoPTX, respectively, by size exclusion 
chromatography using a NAP-10 Sephadex G25 column (GE Healthcare, Buckinghamshire, UK) 
according to the manufacturer’s recommended protocol.  Briefly, 750 µL of exoPTX were added 
to the NAP-10 column and the void volume was discarded.  250 µL of PBS was then added to 
the column and allowed to enter the gel bed completely and the eluate was discarded.  1.2 mL of 
PBS was then added to the column and the eluate containing purified exoPTX was collected and 
stored at -20°C. 
Quantification of Drug Loading 
The amount of PTX loaded into exosomes was measured by a high performance liquid 
chromatography (HPLC) method.  Briefly, exoPTX or exoPTX-AA (1010 exosomes/0.1mL) in a 
microcentrifuge tube was placed on a heating block set to 75°C to evaporate solvent.  After all 
solvent had evaporated, an equal volume of acetonitrile was added to the microcentrifuge tube 
and the mixture was vortexed, sonicated, and vortexed again.  The sample was then centrifuged 
at 13,000 rpm (Thermo Legend Micro 21, Thermo Fisher Scientific, Waltham, MA, USA) for 10 
min.  Following centrifugation, the supernatant was taken and filtered through a Corning 
Regenerated Cellulose .2 µm syringe filter and transferred into HPLC autosampler vials.  20 µL 
aliquots were injected into the HPLC system (Agilent 1200, Agilent Technologies, Palo Alto, 
CA, USA).  All analyses were performed using a C18 column (Supelco Nucleosil C18, 250 mm 
x 4.6 mm, 5 µm, 100 Å, Sigma-Aldrich,) with a mobile phase of H2O:acetonitrile (45:55, v/v) at 
a flow rate of 1 mL/min at 30°C.  Absorbance was measured at 227 nm to monitor the elution of 
PTX.  The area under the PTX peak was measured for each sample and compared with known 
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concentration of standard.  A calibration curve was constructed by plotting peak area versus 
concentrations of paclitaxel and was found to be linear within the tested concentration range (r2 = 
.997).  Exosomal protein content was measured using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s recommended 
protocol. Loading capacity is expressed by µg protein of exosomes. 
Synthesis of DSPE-PEG-AA 
The synthesis was carried out according to the published synthetic protocol with little 
adjustment[23]. Briefly, to synthesize the N-(2-bromoethyl)-4-methoxy-benzamide, 4-
methyoxybenzoyl chloride (1g, 5.8 mmol) in 50 mL of pre-warmed benzene was mixed with an 
aqueous solution of 2-bromoethylamine hydrobromide (1.32g, 6.4 mmol). The emulsion was 
shaken and cooled in running water during the dropwise addition of 5% aqueous solution of 
sodium hydroxide. The precipitate was solidified out of the reaction mixture within a few 
minutes to an amorphous mass. The mixture was continuously stirred for 1h, after which time the 
sold amide was filtered with suction and washed once with benzene and air dried for 2-3h. Then, 
the synthesized N-(2-bromoethyl)-4-methoxy-benzamide (100 mg, 0.4 mmol) was reacted with 
DSPE-PEG-NH2 (100 mg, 23.3 µmol) in acetonitrile (5 mL) in the presence of DIPEA (30 uL, 
0.2 mmol) at 65-70 °C for 16h. After evaporating the solvent, 5 mL of methanol was added to 
dissolve the pellet followed by excess ether (50mL) and it was the kept at -80 °C overnight. The 
precipitate was collected after centrifugation and recrystallized twice. The overall yield was 
70%. The products was characterized by NMR and TLC as reported elsewhere[129]. 
Preparation of Vectorized Exosomes 
Vectorized exosomes targeted to sigma receptor using DSPE-PEG-AA and loaded with 
PTX (exoPTX-AA) were prepared as follows: exosomes were isolated as described above and 
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then 10mg/mL DSPE-PEG-AA was added to the exosome solution.  100μL of 10mg/mL PTX in 
EtOH was also added to the mixture of exosomes with DSPE-PEG-AA when preparing exoPTX-
AA.  The mixture was then sonicated by the same method used by our lab previously [130].  
Briefly, the mixture was sonicated using a Model 505 Sonic Dismembrator with .25” tip 
(Thermo Fisher Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s 
on/off.  After sonication, the solution was incubated at 37°C for 60 min to allow for recovery of 
the exosomal membrane.  Excess free PTX and DSPE-PEG-AA were separated from exoPTX-
AA or exoAA by size exclusion chromatography using a NAP-10 Sephadex G50 column (GE 
Healthcare, Buckinghamshire, UK) according to the manufacturer’s recommended protocol.  
Briefly, 750 µL of exoPTX-AA was added to the NAP-10 column packed with Sephadex G50 
and the void volume was discarded.  250 µL of PBS was then added to the column and allowed 
to enter the gel bed completely.  1.2 mL of PBS was then added to the column and the eluate 
containing purified exoPTX-AA was collected and stored at -20°C.  Loading capacity was 
determined by HPLC and formulations were evaluated to determine which provided the greatest 
drug loading. 
Characterization of Exosomes 
Nanoparticle Tracking Analysis (NTA). Exosomes were identified and characterized 
using NanoSight LM 10 instrument (NanoSight Ltd., Amesbury, UK).  The settings were 
optimized and kept constant between samples, and each video was analyzed using the Nanosight 
system to obtain the size and concentration of exosomes.  The stability of exosomes was 
monitored by measuring size over a period of time under various conditions (4°C, room 
temperature, or 37°C).  Prior to measurement, exosomes were diluted 1:1000 to yield a particle 
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concentration in the region of ~108 particles/mL, in accordance with the manufacturer’s 
recommendations.  All samples were analyzed in triplicate.   
Dynamic Light Scattering (DLS). The average hydrodynamic diameter and zeta potential 
of exosomes was measured by DLS using a Malvern Zetasizer Nano ZS system (Malvern, 
Worcestershire, UK) equipped with He–Ne laser (5 mW, 633 nm) as the light source at 22°C.  
All samples were analyzed in triplicate. 
Atomic Force Microscopy (AFM). The morphology of exoPTX was investigated by AFM 
imaging. ExoPTX formulations were diluted in PBS and a drop of the sample was placed on a 
glass slide and dried under a flow of argon gas. The AFM imaging instrumentation was operated 
as described earlier[131]. 
Western Blot Analysis. The levels of proteins constitutively expressed in exosomes, Alix 
and flotillin 1, as well as the lymphocyte function associated antigen-1 (LFA1, subunit CD11a), 
were examined by western blot (WB). Protein concentrations were determined using BCA kit 
(Pierce Biotechnology, Rockford, IL). The protein bands were detected with Alix, flotillin 1, and 
CD11a primary monoclonal antibodies, (Abcam, Cambridge, UK; 1:1000 dilution), and 
secondary HRP-conjugated rabbit anti-goat IgG-HRP (Santa Cruse, CA, USA; 1:5000 dilution). 
The TSG101 levels were visualized by TSG101 monoclonal antibodies, Abcam 
(Cambridge, MA, USA). The protein bands were visualized by chemiluminescent substrate 
(Pierce Biotechnology, Rockford, IL, USA) and quantified using ImageJ software (National 
Institute of Health, Bethesda, MD, USA)[132]. To correct for loading differences in cellular 
lysates and exosomal fractions, the levels of proteins were normalized to constitutively expressed 
β-actin in cells with goat polyclonal antibodies to β-actin (Abcam, ab8229; 1:500 dilution); and 
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TSG101 in exosomes with goat polyclonal antibodies to TSG101 (Santa Cruz, SC6037; 1:200 
dilution). 
Membrane Fluidity Measurements. BODIPY-PC, a fluorescent dye was used as a probe 
to examine the fluidity properties of exosomal membranes as described earlier[133]. Briefly, 30 
μL exosomes with concentration 4x1011 particles/mL were mixed with 20 μL BODIPY-PC (0.03 
mg/ml) and supplemented with 70 μL deionized water; the mixture was incubated for 45 min at 
37°C in darkness. Unbound label was removed using a ZebaTM column (Life Technologies). 
BODIPY-PC is a hydrophobic fluorescent compound which incorporates into the hydrocarbon 
regions of lipid membranes. Transfer of BODIPY-PC from the aqueous environment into the 
lipid bilayers results in a drastic increase of the fluorescence emission for this probe. 
Furthermore, once the probe is incorporated into lipid membranes, its fluorescence polarization 
is strongly dependent on the microenvironment, with decreases in membrane microviscosity 
resulting in increased fluorescent polarization. Fluorescence intensities were measured with 
Spectramax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). An excitation 
wavelength of 495 nm and an emission wavelength of 502 nm were used for both probes. 
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RESULTS 
Isolation and Characterization of Exosomes from RAW 264.7 Macrophages 
Exosomes were collected from the conditioned media of RAW 264.7 macrophages using 
a polymer purification method (ExoQuick-TC™) and were characterized by protein content, 
size, and morphology.  Exosomes had elevated expression of exosome-associated proteins (Alix, 
TSG101, and Flotillin) as compared to cell lysate, which had greater levels of β-actin (Figure 
1A).   
 
Figure 1.4. Characterization of PTX exosomal formulations. 264.7 macrophages were collected from 
conditioned media, and the exosome protein content was confirmed by western blot (A). Exosomes were loaded 
with PTX by various methods: co-incubation at RT; electroporation, and sonication. The size of the exosomes with 
incorporated PTX was measured by NTA and DLS (C). The amount of PTX incorporated into exosomes was 
assessed by HPLC (B). The loading efficiency of exosomes with PTX increased in a row: incubation at RT < 
electroporation<< sonication (C). The morphology of drug-loaded exosomes was examined by AFM (D). Images 
revealed small spherical naïve exosomes, and PTX-loaded exosomes. The bar: 200 nm. LFA1/CD11a expression in 
exosomes as assessed by Western Blot (E).  
1 – cells;  2 - exosomes 
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Exosomes were also found to express the lymphocyte function associated antigen-1 
(LFA1, subunit CD11a) (Figure 1E), which assists in cell uptake and may bind to endothelial 
cell adhesion molecules which are overexpressed on activated endothelial cells such as those 
found in tumors[134].  Naïve empty exosomes had a narrow size distribution, with an average 
particle diameter of 110.4 ± 4.2 nm and 70.8 ± 2.8 nm as revealed by NTA and DLS, 
respectively (Figure 1C); and a round morphology as shown by AFM imaging (Figure 1D). 
Manufacture and Characterization of Exosomal Formulations of PTX (exoPTX) 
PTX was incorporated into exosomes using three different methods: a) incubation at RT, 
b) electroporation, and c) mild sonication, as described in the Materials and Methods section. 
ExoPTX formulations were purified from non-incorporated drug by size-exclusion 
chromatography and analyzed by HPLC to determine the loading capacity (LC) of exosomal 
carriers. The typical HPLC profile for PTX extracted from exosomes (I) and PTX standards (II) 
are shown in Figure 1.4B. HPLC analysis revealed that the amount of PTX loaded into 
exosomes increased as follows: incubation at RT < electroporation << sonication (Figure 1.4C). 
We suggested that a reorganization of exosomes caused by ultrasound treatment may result in 
reorganization/reshuffling of exosomal membranes that enables PTX diffusion across relatively 
tight and highly structured lipid bilayers. Indeed, fluorescence polarization measurements 
revealed significant increases (more than 2x) in membrane fluidization upon sonication (Figure 
1.5), which allowed the high loading efficiency of exosomal carriers. Noteworthy, after one hour, 
the membrane microviscosity was restored. As such, exosomes were incubated for one hour at 
37°C after sonicating in order to restore exosome membrane integrity. 
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Figure 1.5. Effect of sonication on fluidity of exosomal membranes.  Exosomes isolated from RAW 264.7 
macrophages concomitant media were labeled with BODIPY-PC fluorescent dye as described in Materials section, 
and subjected to one or 6 cycles of ultrasound treatment. The fluorescence polarization was measured right after the 
sonication, or following 30 min or 1 hour incubation period at 37C. Values are means ± SEM (n = 4). Symbols indicate 
the relative level of significance compared with naive exosomes. 
 
Interestingly, DLS studies revealed that the size of exoPTX nanoformulations increased 
similarly, with the smaller being exoPTX nanoparticles obtained by electroporation or incubation 
at RT, and the larger being exosomes loaded with PTX by sonication (Figure 1.4C). 
Noteworthy, NTA analysis confirmed these results indicating that the size of exoPTX obtained 
by sonication is about 1.5x greater than naïve empty exosomes (Figure 1.4C). Interestingly, 
exosomes sonicated in the absence of PTX (average size 326.0 ± 23.5 nm by NTA, and 356.1 ± 
3.5 nm by DLS) were even larger than exosomes sonicated with PTX solution (217.9 ± 10.1 nm). 
We hypothesized that incorporation of PTX into exosomal membranes stabilized these 
aggregates. Furthermore, all mentioned loading procedures did not significantly alter the zeta 
potential of the nanocarriers (Figure 1.4C). It is known that the anionic phospholipid 
phosphatidylserine is abundant on cell membranes and contributes to the surface charge of 
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individual cellular membranes. We speculated that all of the PTX loading procedures caused no 
major alterations the lipid content of exosomal membranes.  Thus, AFM imaging showed that 
exosomes retained their round morphology upon sonication (Figure 1.4D), suggesting that this 
procedure did not significantly disrupt the structure of exosomes.  
Overall, the mild sonication procedure provided the highest amount of drug loading; the 
obtained LC of 28.29 ± 1.38% was much higher than the LC of commercially available 
formulations of PTX, Taxol (~1% LC) or Abraxane (~10% LC).  We hypothesized that the 
application of ultrasound creates pores in exosomes which allows for PTX to incorporate into the 
hydrophobic lipid bilayer of the exosome without destroying the exosome membranes. Because 
of the high LC, exoPTX produced by sonication was selected for further experiments. 
Manufacture and Characterization of Exosomal Formulations of PTX Vectorized to the 
Sigma Receptor (exoPTX-AA) 
The sigma receptor is overexpressed by many types of cancer, including NSCLC, making 
 
Figure 1.6. Overexpression of  receptor in lung cancer cells. (A) Western blot analysis revealed a significant 
amount of  receptor in cancer cells, but not in normal lung fibroblasts. (B) Relative expression of target receptors 
to -actin.  
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it an attractive target for cancer therapy [20-23]. In order to validate the sigma receptor as a 
target for our Lewis Lung Carcinoma 3LL-M27 cell line used in our mouse model of metastatic 
lung cancer, a Western Blot was performed to look for the presence of the sigma receptor in 
3LL-M27 cells.  Western Blot analysis revealed overexpression of the sigma receptor in target 
3LL-M27 cells (Figure 1.6A), indicating that the choice of anisamide (a sigma receptor ligand) 
as a vector to target 3LL-M27 cells is appropriate.   
 
Figure 1.7 Optimization and Characterization of exoPTX-AA.  (A) Varying amounts of DSPE-PEG-AA were 
added to exosome with 1mg paclitaxel, and the mixture was sonicated to produce vectorized and paclitaxel-loaded 
exosomes (exoPTX-AA).  HPLC analysis of each formulation revealed the loading capacity (LC), and the formulation 
providing the greatest LC while maximizing the amount of DSPE-PEG-AA was chosen (.25mg DPSE-PEG-AA).  (B) 
The exoPTX-AA formulation was characterized by DLS to obtain the Z-average size and zeta potential.  LC was 
determined by HPLC.   
 
We hypothesize that reorganization of exosomes caused by ultrasound treatment may 
result in the reorganization/reshuffling of the exosomal membrane, enabling PTX and DSPE-
PEG-AA diffusion across relatively tight and highly structured lipid bilayers.  Exosomes were 
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loaded with PTX and vectorized to target the sigma receptor using the sonication method 
developed by our lab [29].  Varying amounts of vector were added to exosomes with paclitaxel 
in order to determine the optimal formulation providing the greatest loading capacity while 
maximizing the amount of vector.  HPLC analysis of the formulations revealed that the optimal 
amount of DSPE-PEG-AA to add in order to achieve the greatest loading capacity was 0.25 mg, 
thus this formulation was chosen for further study (Figure 1.7A). HPLC analysis revealed that 
the loading capacity of the optimal formulation of exoPTX-AA was 33.42 ± 3.22%, similar to 
the loading capacity achieved by exoPTX alone without vector (28.29 ± 1.38%) (Figure 1.7B). 
Further characterization by DLS showed that exoPTX had a smaller size (287.7 ± 0.7nm) 
than exoPTX-AA (304.5 ± 3.85 nm) (Figure 1.7B).  We hypothesize that this size increase as 
measured by DLS is due to the presence of the long PEG chains of DSPE-PEG-AA on the 
surface of exoPTX-AA, as well as the insertion of DSPE lipids into the exosomal lipid 
membrane.  The surface charge of exoPTX was found to be -14.07 ± 0.94 mV, whereas exoPTX-
AA had a surface charge of -4.37 ± 0.09 mV (Figure 1.7B).  We hypothesize that this decrease 
in observed surface charge may be due to shielding of the exosomal membrane surface charge by 
DSPE-PEG-AA. 
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DISCUSSION 
Although various drug nanoformulations have been developed to improve the therapeutic 
effect of drugs, there are still issues that significantly diminish their application in clinic, e.g. 
toxicity and rapid clearance by the mononuclear phagocyte system (MPS) [135].  In fact, the 
safety of drug nanoformulations is the subject of substantial criticism. In this respect, exosomes, 
naturally-produced nanosized vesicles secreted by a variety of cells, represent an important tool 
for both diagnostic and therapeutic purposes. Exosomes consist of cellular membranes with a 
variety of adhesion proteins on their surface [136] which allow for efficient transport of 
exosomal cargo into target cells.  Exosomes have been reported for use as drug delivery vehicles 
for nucleic acids [5, 8, 10, 103, 117, 137] and small molecule drugs such as curcumin [89, 90], 
anticancer agents (Dox [92, 93] and PTX [94]). The low molecular-weight compounds were 
loaded into exosomes or exosome-like vesicles by co-incubation at RT. These studies 
demonstrated the feasibility of using an exosomal formulation for cancer therapy as well as for 
neurodegenerative disorders. We also reported recently the development of a new exosome-
based formulation of potent antioxidant, catalase, to treat Parkinson’s disease [106]. A large 
protein, catalase (MW 240 K), was loaded into exosomes using different procedures: sonication, 
extrusion, and permeabilization of exosomal membranes with saponin.  The extensive 
reformation and reshaping of exosomes upon sonication and extrusion, as well as the creation of 
holes/pores in the exosome lipid bilayer by saponin, enabled catalase to diffuse across relatively 
tight and highly structured lipid bilayers and resulted in high loading efficiency of exosomal 
carriers [106]. 
PTX is a potent chemotherapeutic used to treat many forms of cancer, however, its 
effectiveness for clinical use is hampered by its low aqueous solubility. There have been 
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significant efforts to formulate PTX into various nanoformulations to increase solubility and 
improve pharmacokinetics, including polymer based nanoparticles and liposomes.  However, 
these systems possess several undesirable properties such as the presence of toxic excipients 
and/or rapid clearance by the endothelial system (RES).  
In the present study, we utilized various methods for PTX incorporation into exosomes: 
incubation at RT, electroporation, and mild sonication. Mild sonication of exosomes in the 
presence of PTX, provided the greatest loading capacity (28.29% ± 2.58%). PTX is a highly 
hydrophobic compound, therefore we hypothesized that this drug is incorporated into the 
hydrophobic inner region of the phospholipid bilayer of exosomes.  Indeed, exosome membranes 
display a high rigidity that was significantly decreased upon sonication. We hypothesized that 
the membrane fluidization allowed PTX incorporation into lipid bilayers resulting in the high 
loading capacity of exosomal carriers.  The precise location of PTX in exosomes will be 
investigated in future studies.  Importantly, drug located in the inner bilayer of exosomes may 
also be available for use: as the exosomal membrane fuses with the cell or endosomal membrane, 
its intraluminal cargo may be released into the cytosol.  Next, we assessed the optimal 
concentration of DSPE-PEG-AA to add to exosomes which would provide the greatest drug 
loading capacity.  DSPE is a lipid, thus we hypothesize that DSPE would insert into the lipid 
bilayer of the exosomal membrane upon sonication.  The optimal formulation of exoPTX-AA 
was found to have a loading capacity (33.42% ± 3.22%) similar to that of exoPTX (28.29% ± 
2.58%) and a slightly larger size (304.5 ± 3.85 nm for exoPTX-AA vs. 287.7 ± 0.7 nm for 
exoPTX).  The size increase may be due to the presence of long PEG chains on the surface of 
exoPTX-AA, as well as an increased surface area due to insertion of the DSPE lipid into the 
exosomal membrane.  A slight decrease in zeta potential for exoPTX-AA as compared to 
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exoPTX was also observed, again, this may be caused by shielding of the exosomal membrane 
by long PEG chains on the surface of exoPTX-AA. 
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CHAPTER 2. IN VITRO CHARACTERIZATION OF exoPTX AND exoPTX-AA3 
OVERVIEW 
Multiple drug resistance (MDR) is a factor which severely limits the efficacy of a variety of 
chemotherapeutics, including paclitaxel. MDR may be intrinsic or acquired [1,2] and is mediated 
by different mechanisms, in particular, the overexpression of the drug efflux transporter P-
glycoprotein (Pgp). As a result, the response rate following treatment remains very low for many 
types of malignancies, including acute leukemias, malignant gliomas, metastatic breast cancer, 
and other cancers [1-3]. Prior treatment with antineoplastic agents is a serious adverse prognostic 
factor for many cancers due to the acquiring of drug resistance, resulting in low long-term 
survival rates for patients with recurring cancers [3,4]. To date, there has been limited success in 
overcoming drug resistance in cancers through the use of novel small molecule 
chemotherapeutics [7,8], or nanoformulations of existing chemotherapeutics.  In addition, 
various Pgp inhibitors, such as quinine or cyclosporine A, have been co-administered with 
chemotherapeutic agents [138, 139].  These efforts did result in improved patient outcomes, 
however, the non-specific inhibition of Pgp frequently increased drug toxicity due to alteration of 
drug elimination pathways in the liver, kidney, etc. [140]. 
                                                          
3 Some of this text previously appeared in an article in the journal Nanomedicine.  The original citation is as 
follows: Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells. Myung Soo Kim, 
Matthew J. Haney, Yuling Zhao, Richa Gupta, Zhijian He, Natalia L. Klyachko, Aleksandr Piroyan, Marina Sokolsky, 
Alexander v. Kabanov, and Elena V. Batrakova. Nanomedicine, Nov 13. pii: S1549-9634(15)00202-6. doi: 
10.1016/j.nano.2015.10.012. PMID: 26586551 
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Herein, we have developed a new nanoformulation consisting of exosomes loaded with PTX 
(exoPTX), a commonly used chemotherapeutic agent, and vectorized to target the sigma 
receptor. The main objectives of this study were: (i) to assess the feasibility of using exoPTX for 
MDR-related anticancer therapy, (ii) to identify mechanisms underlying inhibitory effects of 
exosomes on drug efflux pump in Pgp expressing cancer cells, (iii) to prepare and assess the 
targeting ability of exosomes vectorized to the sigma receptor, and (iv) to assess the intracellular 
fate of exosomes and vectorized exosomes. 
Results showed that exoPTX were readily taken up by multiple cancer cell types and 
exhibited greater cytotoxicity than Taxol in vitro, especially in MDR cancer cells. Vectorized 
exosomes were able to successfully be taken up by target cancer cells expressing the sigma 
receptor by receptor mediated endocytosis, and their intracellular fate was not altered by the 
addition of the vector.  Finally, vectorized exosomes loaded with paclitaxel (exoPTX-AA) 
exhibited greater cytotoxicity than Taxol and similar cytotoxicity to exoPTX in vitro. Overall, 
exosome-based PTX formulations have the potential to be a versatile strategy to treat drug 
resistant cancers. 
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MATERIALS AND METHODS 
Reagents 
Paclitaxel (PTX) was purchased from LC Laboratories (Woburn, MA, USA).  The stock 
solution was prepared in ethanol (EtOH) at a concentration of 10 mg/mL.  Aliquots were stored 
at -20°C.  Doxorubicin (DOX) was purchased from LC Laboratories (Woburn, MA, USA).  The 
stock solution was prepared in DMSO at a concentration of 2 mg/mL and aliquots were stored at 
4°C.  Working solutions of PTX or DOX were prepared fresh according to experimental design 
by serial dilution in an appropriate medium.  A lipophilic fluorescent dye, 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindo-carbocyanine perchlorate (DIL), was purchased from Invitrogen 
(Carlsbad, CA, USA).  Rhodamine 123 (R123), 4′,6-diamidino-2-phenylindole dihydrochloride 
(DAPI), and Triton X-100 were obtained from Sigma-Aldrich (St. Louis, MO, USA).  Cell 
culture medium and fetal bovine serum (FBS) were purchased from Gibco Life Technologies, 
Inc. (Grand Island, NY, USA). Culture flasks and dishes were from Corning Inc. (Corning, NY, 
USA).  Fluorescent polystyrene nanoparticles (Fluoro-Max G100) were obtained from Thermo 
Fisher Scientific (Waltham, MA, USA).  ExoQuick-TC™ Exosome Precipitation Solution was 
obtained from System Biosciences (Mountain View, CA, USA).  ER Tracker Blue-White DPX, 
LysoTracker Green DND-26, and MItoTracker Deep Red were purchased from Thermo Fisher 
(Thermo Fisher Scientific, Waltham, MA, USA). 
Cells 
RAW 264.7 macrophages, Madin-Darby canine kidney MDCKWT and MDCKMDR1 cells 
(purchased from ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) high glucose (Gibco, Grand Island, NY, USA) supplemented with 10% fetal 
bovine serum (FBS; Thermo Fisher Scientific), 1% penicillin and streptomycin at 37°C and 5% 
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CO2.  Murine Lewis lung carcinoma cell subline (3LL-M27), a highly metastatic lung clone, was 
a generous gift from Dr. L. Pelletier (CHUL, Laval University, QC, Canada), and were cultured 
in DMEM high glucose supplemented with 10% FBS, 10 mM HEPES, 1% penicillin and 
streptomycin at 37°C and 5% CO2.   
Pgp protein levels in sensitive and resistant cancer cells were determined by western blot 
as previously reported [22] using monoclonal antibodies to Pgp, C219 (Dako Corp., Carpinteria, 
CA, USA; at dilution 1:100), and secondary horseradish peroxide donkey anti-mouse IgG 
antibodies (Amersham Life Sciences, Cleveland, OH, USA; at dilution 1:1500). To correct for 
loading differences, the Pgp levels were normalized to the constitutively expressed β-actin 
(stained with monoclonal antibodies to β-actin, anti-β-1-chicken integrin (Sigma Chemical Co., 
at dilution 1:200)). Specific bands were visualized using a chemiluminescence kit (Pierce, 
Rockford, IL, USA). 
Exosome Isolation 
For all studies, exosome-depleted media was prepared by ultracentrifugation of fetal 
bovine serum (FBS) at 120,000 x g for 110 min to remove all vesicular content prior to addition 
to media.  Exosomes were harvested from the supernatants of RAW 264.7 cells cultured in 
exosome-depleted media using the ExoQuick-TC™ Kit (System BioSciences; Mountain View, 
CA, USA).  Briefly, > 90% confluent RAW 264.7 cells were cultured in exosome-depleted 
media for 2 days.  50 mL conditioned cell culture media were centrifuged at 300 x g for 10 min 
(Thermo CL-10 centrifuge with O-G26/1 rotor, Thermo Fisher Scientific, Waltham, MA, USA) 
in order to remove cells and cellular debris.  The supernatant was then taken, filtered with a .22 
µm PES filter, and ExoQuick-TC™ Exosome Precipitation Solution (System Biosciences, 
Mountain View, CA, USA) was added to the filtered supernatant and the mixture was vortexed 
43 
 
and incubated overnight at 4°C.  After overnight incubation, the mixture was vortexed again and 
subsequently centrifuged at 1500 x g for 30 min. and 5 min. to pellet exosomes.  The supernatant 
was discarded and the exosome pellet was resuspended in PBS.  Freshly-prepared exosomes or 
exosomes stored at -20°C were used for all experiments. 
Drug Loading into Exosomes 
For PTX and DOX loading into exosomes, purified exosomes (~1011 exosomes) were 
first mixed with PTX or DOX in 1 mL PBS.  First, PTX was dissolved in ethanol (EtOH, 10 
mg/ml drug in EtOH stock solution) and added to 1 mL exosomes. DOX stock solution was 
prepared in DMSO (2 mg/mL) and added to 1mL exosomes. The PTX-exosome or DOX-
exosome mixture was then sonicated using a Model 505 Sonic Dismembrator with .25” tip 
(Thermo Fisher Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s 
on/off for three minutes with a two minute cooling period between each cycle.  After sonication, 
PTX-loaded exosomes (exoPTX) or DOX-loaded exosomes (exoDOX) solution was incubated at 
37°C for 60 min to allow for recovery of the exosomal membrane.  
Excess free PTX or DOX was separated from exoPTX or exoDOX, respectively, by size 
exclusion chromatography using a NAP-10 Sephadex G25 column (GE Healthcare, 
Buckinghamshire, UK) according to the manufacturer’s recommended protocol.  Briefly, 750 µL 
of exoPTX or exoDOX were added to the NAP-10 column and the void volume was discarded.  
250 µL of PBS was then added to the column and allowed to enter the gel bed completely and 
the eluate was discarded.  1.2 mL of PBS was then added to the column and the eluate containing 
purified exoPTX or exoDOX was collected and stored at -20°C. 
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For mechanistic studies, two fluorescent dyes used as model Pgp substrates, Rhodamine 
123 (Rh123) and Doxorubicin, were incorporated into exosomes as described above. 
Doxorubicin was chosen as it is actually an antinreoplastic agent and a Pgp substrate.   
ExoPTX Stability 
The stability of exoPTX was assessed at 4°C, RT, and at 37°C.  Briefly, samples of 
exoPTX were stored at different temperatures for varying lengths of time.  After each time point, 
samples were analyzed by NTA to assess their size. 
Quantification of Drug Loading 
The amount of PTX loaded into exosomes was measured by a high performance liquid 
chromatography (HPLC) method.  Briefly, exoPTX (1010 exosomes/0.1mL) in a microcentrifuge 
tube was placed on a heating block set to 75°C to evaporate solvent.  After all solvent had 
evaporated, an equal volume of acetonitrile was added to the microcentrifuge tube and the 
mixture was vortexed, sonicated, and vortexed again.  The sample was then centrifuged at 13,000 
rpm (Thermo Legend Micro 21, Thermo Fisher Scientific, Waltham, MA, USA) for 10 min.  
Following centrifugation, the supernatant was taken and filtered through a Corning Regenerated 
Cellulose .2 µm syringe filter and transferred into HPLC autosampler vials.  20 µL aliquots were 
injected into the HPLC system (Agilent 1200, Agilent Technologies, Palo Alto, CA, USA).  All 
analyses were performed using a C18 column (Supelco Nucleosil C18, 250 mm x 4.6 mm, 5 µm, 
100 Å, Sigma-Aldrich,) with a mobile phase of H2O:acetonitrile (45:55, v/v) at a flow rate of 1 
mL/min at 30°C.  Absorbance was measured at 227 nm to monitor the elution of PTX.  The area 
under the PTX peak was measured for each sample and compared with known concentration of 
standard.  A calibration curve was constructed by plotting peak area versus concentrations of 
paclitaxel and was found to be linear within the tested concentration range (r2 = .997).  
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Exosomal protein content was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s recommended protocol. 
Loading capacity is expressed by µg protein of exosomes. 
Synthesis of DSPE-PEG-AA 
The synthesis was carried out according to the published synthetic protocol with little 
adjustment[23]. Briefly, to synthesize the N-(2-bromoethyl)-4-methoxy-benzamide, 4-
methyoxybenzoyl chloride (1g, 5.8 mmol) in 50 mL of pre-warmed benzene was mixed with an 
aqueous solution of 2-bromoethylamine hydrobromide (1.32g, 6.4 mmol). The emulsion was 
shaken and cooled in running water during the dropwise addition of 5% aqueous solution of 
sodium hydroxide. The precipitate was solidified out of the reaction mixture within a few 
minutes to an amorphous mass. The mixture was continued stirred for 1h, after which time the 
solid amide was filtered with suction and washed once with benzene and air dry for 2-3h. Then, 
the synthesized N-(2-bromoethyl)-4-methoxy-benzamide (100 mg, 0.4 mmol) was reacted with 
DSPE-PEG-NH2 (100 mg, 23.3 µmol) in acetonitrile (5 mL) in the presence of DIPEA (30 uL, 
0.2 mmol) at 65-70 °C for 16h. After evaporating the solvent, 5 mL of methanol was added to 
dissolve the pellet followed by excess ether (50ml) and it was the kept at -80 °C overnight. The 
precipitate was collected after centrifugation and recrystallized twice. The overall yield was 
70%. The products was characterized by NMR and TLC as reported elsewhere[129]. 
Preparation of Exosomes Vectorized to the Sigma Receptor 
Vectorized exosomes targeted to sigma receptor using DSPE-PEG-AA (exoAA) and non-
vectorized control exosomes with DSPE-PEG (exoPEG) were prepared as follows: exosomes 
were isolated as previously described and then varying volumes of 10mg/mL DSPE-PEG or 
DSPE-PEG-AA were added to the exosome solution (for exoPEG and exoAA, respectively).  
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100μL of 10mg/mL PTX in EtOH was also added to the mixture when preparing exoPTX-AA.  
The mixture was then sonicated by the same method used by our lab previously [29].  Briefly, 
the mixture was sonicated using a Model 505 Sonic Dismembrator with .25” tip (Thermo Fisher 
Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s on/off.  After 
sonication, the exoAA or exoPEG solution was incubated at 37°C for 60 min to allow for 
recovery of the exosomal membrane.  Excess free DSPE-PEG or DSPE-PEG-AA was separated 
from exoPEG or exoAA, respectively, by size exclusion chromatography using a NAP-10 
column packed with Sepharose 6b (GE Healthcare, Buckinghamshire, UK) according to the 
manufacturer’s recommended protocol.  Briefly, 750 µL of exoPEG or exoAA were added to the 
NAP-10 column packed with Sephadex 6b and the void volume was discarded.  250 µL of PBS 
was then added to the column and allowed to enter the gel bed completely.  1.2 mL of PBS was 
then added to the column and the eluate containing purified exoPEG or exoAA was collected and 
stored at -20°C. 
Drug Release 
To measure PTX release, freshly prepared exoPTX were placed in a 300K MWCO Float-
A-Lyzer G2 device (Spectrum Laboratories, Houston, TX, USA).  The device was then placed in 
PBS under sink conditions at RT with stirring.  Samples were taken at time points from inside 
the dialysis tube and were analyzed by HPLC as described above.  The amount of PTX released 
from exoPTX was expressed as a percentage of total PTX and plotted as a function of time. 
Preparation of Liposomes 
Liposomes were prepared by a reverse phase evaporation method. Briefly, 2 mg of 
phospholipids (95 molar % of phosphatidyl choline and 5% of PEG-PE) were dissolved in 6 mL 
of chloroform:diisopropyl ether in a 1:1 mixture. Then, 1 mL of 5 mM calcein solution in PBS 
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filtered through a 450 nm syringe filter and was added to the mixture. The mixture was then 
intensively vortexed and bath sonicated to form a stable emulsion. Organic solvents were 
evaporated on a rotary evaporator, forming the liposome aqueous dispersion. 200-250 µL of 
Millipore water was added to the mixture at this point in case some water had also evaporated. 
Evaporation was continued to get an almost-clear dispersion. The volume was then adjusted to 
1000 µL by addition of a small amount of water. The dispersion was vortexed and bath sonicated 
to get a clear solution. Liposomes were sequentially extruded 21 times through 200 nm 
polycarbonate filters using a hand extruder (Avanti Polar Lipids, Alabaster, AL, USA).  
Liposomes were purified through a Sepharose CL4B column to remove non-encapsulated 
fluorophore. The volume of the sample was doubled after column separation. Calcein loaded 
liposomes were used within 24 h after column separation. 
Accumulation of Exosomes and Exosome-incorporated PTX in Cancer Cells 
To quantify the amount of exosomes taken up by cells, exosomes were first stained with a 
lipophilic fluorescent dye, DiL.  Briefly, the supernatant of RAW 264.7 macrophage conditioned 
media free of cells and cellular debris was filtered with a .22 µm PES filter and incubated with 
DiL dye (4 µM) at 37°C for 20 min.  After 20 min, ExoQuick-TC™ Exosome Precipitation 
Solution was added to the filtered supernatant and the mixture was vortexed and incubated 
overnight at 4°C.  After overnight incubation, the mixture was vortexed again and subsequently 
centrifuged at 1500 x g for 30 min. and 5 min. to pellet exosomes.  The supernatant was 
discarded and the exosome pellet was resuspended in PBS.  Freshly-prepared fluorescently 
labeled exosomes or exosomes stored at -20°C were used for all experiments. 
3LL-M27 cells were seeded overnight at 10,000 cells/well on borosilicate chamber slides.  
DiL-labeled exosomes, or fluorescently-labeled polystyrene nanoparticles (Fluoro-Max G100, 
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Thermo Fisher Scientific, USA), were added in equal numbers (~108 particles/well) and 
incubated with the cells at 37°C and 5% CO2 for 3 or 24 hrs.  After each time point, the media 
was removed and cells were washed 3x with PBS and fixed by incubating with Formal-Fixx 
(Thermo Fisher Scientific) for 15 min at 23°C.  Then, Formal-Fixx was removed, and cells were 
washed with PBS, and fluorescence in each sample was measured by Shimadzu RF5000 
fluorescent spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD). 
To study the effect of PTX incorporation into exosomes on the level of drug 
accumulation in cancer cells, 3LL-M27, MDCKWT, or MDCKMDR1 cells were seeded overnight 
at 100,000 cells/well in a 24-well plate.  ExoPTX or Taxol were added in equimolar amounts to 
the cells and incubated for 72h.  The media was then removed; 3LL-M27 cells were detached 
using a cell scraper and MDCK cells were washed with PBS and incubated with 0.25% trypsin 
for 5-15 min at 37°C.  The cell suspension was then mechanically lysed via sonication and 
analyzed for PTX content by HPLC as described above and protein content by BCA assay 
according to the manufacturer’s recommended protocol. 
Confocal Studies 
Exosomes were labeled with DiL as described above.  Fluorescently-labeled exosomes, 
liposomes, or polystyrene nanoparticles (~108 particles/well) were incubated with 3LL-M27 
cells grown in chamber slides (1x105 cells/chamber) for 3 h.  Following incubation, cells were 
washed with PBS and fixed with Formal-Fixx.  Accumulation of fluorescently-labeled exosomes 
was visualized by a confocal fluorescence microscopic system ACAS-570 (Meridian 
Instruments, Okimos, MI, USA) with argon ion laser and corresponding filter set. Digital images 
were obtained using the CCD camera (Photometrics, Tucson, AZ, USA). 
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Effect of Pgp Inhibitor, Verapamil, on the Uptake of Exosome-incorporated Drugs 
To assess the ability of exosome-incorporated drugs to overcome Pgp-mediated drug 
efflux, the accumulation of a Pgp substrate, Doxorubicin (Dox), incorporated into exosomes by 
sonication, was evaluated in MDR cancer cells (MDCKMDR1). The accumulation levels of these 
fluorescent probes were assessed by spectrofluorimetry. For this purpose, Pgp-overexpressing 
MDCKMDR1 cells and their parental sensitive MDCKWT cells were seeded overnight at 100,000 
cells/well in a 96-well plate.  Then, the cells were pre-incubated in assay buffer or verapamil 
(300 μM) for 30 min at 37°C.  Cells were then treated with the free probe, or the probe 
incorporated into exosomes (exoDox), with or without verapamil, for 2 hours. Cells were then 
washed 3x with cold PBS and supplemented with 1% Triton X-100 to lyse the cells.    
Next, to evaluate whether exosomes inhibit Pgp-mediated drug efflux in resistant cancer 
cells, a fluorescent probe and Pgp substrate, Rhodamine 123 (R123), was used in accumulation 
studies. Briefly, MDCKWT and MDCKMDR1 cell monolayers were pretreated with verapamil, or 
empty exosomes, or assay buffer, washed 3x times with PBS, and R123 solution (3.2 uM) was 
added to the cells for 2 hours.  Cells were then washed 3x with cold PBS and supplemented with 
1% Triton X-100 to lyse the cells.   A standard curve of R123 or DOX was prepared in 1% 
Triton X-100 and the fluorescence of samples was measured (*ex = 505 nm, *em = 540 nm for 
R123, and *ex = 480 nm, *em = 594 nm for Dox).  Samples in 1% Triton X-100 were analyzed 
by BCA for protein content. The accumulation levels were expressed as μg R123 or DOX/μg 
protein. All experiments were carried out in triplicate. 
In Vitro Cytotoxicity  
The in vitro antitumor efficacy of exoPTX was assessed using a standard MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazoliumbromide) assay with three cancer cell lines, 
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3LL-M27, MDCKWT and MDCKMDR1, and compared to Taxol.  Briefly, the cells were seeded in 
96-well plates at a density of 5,000 cells per well, followed by 48-hour incubation at 37°C and 
5% CO2.  The cells were incubated with serial dilutions of exoPTX, or Taxol for 48 hours. Then, 
25 µL MTT reagent (5 mg/mL) was added to wells.  After 1-3 h incubation at 37C and 5% CO2 
in the dark, plates were centrifuged at 1500 rpm for 10 min and media was removed from the 
wells.  100 µL of DMSO was then added to each well to solubilize formazan crystals and the 
plates were shaken at 200 rpm for 15 min. in the dark.  Absorbance was measured at 570 nm 
using Spectramax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA), and IC50 
values were determined using GraphPad Prism Software version 5.01 (GraphPad Software, San 
Diego, CA, USA).  Each concentration point was determined from samplings from eight separate 
wells. SEM values were less than 10%. Data are expressed as mean ± SEM. 
Receptor Competitive Inhibition  
In order to assess the ability of exoPTX-AA to target the sigma receptor and be taken up 
by cells expressing the sigma receptor, a receptor competitive inhibition study was performed.  
Briefly, 3LL-M27 cells expressing sigma receptor were seeded overnight at 50,000 cells/well in 
a black/clear bottom 96-well plate.  Cells were pre-treated with anisamide (AA) at varying 
concentrations for 30min at 37°C.  Media was then removed from wells and cells were treated 
with a solution of DiD labeled exoAA with varying concentration of AA.  After 1h, media was 
removed from wells and cells were washed 3x with PBS.  PBS was then removed from wells and 
1% Triton X-100 added to wells to lyse cells.  The plate was then placed in -80°C for 5min., 
followed by shaking at 37°C for 30min.  Excitation/emission was read at 640nm/670nm using a 
Spectramax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA), and the number 
of exosomes taken up at each concentration of AA was determined by comparing the 
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fluorescence against a known concentration of standard.  A calibration curve was constructed by 
plotting fluorescence versus concentrations of DiD exoAA in 1% Triton X-100 and was found to 
be linear within the tested concentration range (r2 = .998).  Cellular protein content was 
measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, 
USA) according to the manufacturer’s recommended protocol and results were expressed as 
number of exosomes per µg protein versus concentration of AA.  Each concentration point was 
determined from samplings from three separate wells. SEM values were less than 10%. Data are 
expressed as mean ± SEM. 
Effect of Proteinase K Treatment on Exosome Uptake 
Exosomes possess a variety of surface proteins which are believed to play a role in cell 
uptake and adhesion, such as LFA-1[134].  In order to explore the role of surface proteins on 
exosome uptake, naïve exosomes, sonicated exosomes (exoSONIC), or exoAA were diluted to 
the same concentration of exosomes (~1011 exosomes/mL) and treated with Proteinase K.  
Briefly, 10µL of 10mg/mL proteinase K or PBS (as a control) were added to 1mL naïve 
exosomes, exoSONIC, or exoAA and incubated at 37°C for 30 min.  Excess free enzyme was 
separated from digested exosomes by size exclusion chromatography using a NAP10 column 
packed with Sepharose CL-6B to the same volume/height according to the manufacturer’s 
recommended instructions.  Briefly, 750µL exosomes were added to the column and the void 
volume was discarded.  250 µL of PBS was then added to the column and allowed to enter the 
gel bed completely and the eluate was discarded.  1.2 mL of PBS was then added to the column 
and the eluate containing purified exosomes was collected and stored at -20°C. Exosomes were 
then labeled with DiL dye as described above.  3LL-M27 cells were seeded overnight in a 
black/clear bottom 96-well plate (Corning Costar, Corning, NY, USA) at 50,000 cells/well.  
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Undigested and digested exosomes were diluted to the same concentration and added to wells for 
varying lengths of time.  After 2h, media was removed from wells and wells were washed 3x 
with PBS.  PBS was then removed from the wells and 50µL of 1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA) was added to each well.  The 96-well plate was then placed at -
80°C for 5 min., followed by incubation at 37°C for 30 min. with shaking.  Excitation and 
emission was read at 540nm and 570nm, respectively, using a Spectramax M5 microplate reader 
(Molecular Devices, Sunnyvale, CA, USA), and compared against a known concentration of 
standard.  A calibration curve was constructed by plotting peak area versus concentrations of 
DiL labeled exosomes, exoSONIC, or exoAA, and was found to be linear within the tested 
concentration range (r2 = .999).  Exosomal protein content was measured using the Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s recommended protocol. Results were expressed as number of exosomes per µg 
protein versus time. 
Intracellular Distribution of Exosomes and Exosomal Proteins and Lipids 
In order to assess the intracellular distribution of exosomes, 3LL-M27 cells were seeded 
at 500,000 cells/well in chamber slides and incubated overnight.  Exosomes or exoAA were 
labeled with DiL as described above and added to wells for varying times.  Media was then 
removed from wells and pre-warmed staining solution (ER Tracker Blue-White DPX, 
LysoTracker Green DND-26, or MitoTracker Deep Red) were added to wells according to the 
manufacturer’s recommended instructions.  Media was then removed from wells and washed 3x 
with PBS.  Cells were then fixed by the addition of Formal-Fixx for 20min. at 37°C followed by 
washing 3x with PBS.  Exosomes and organelles were visualized by confocal fluorescence 
microscopic system ACAS-570 (Meridian Instruments, Okimos, MI, USA) with argon ion laser 
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and corresponding filter set.  Excitation/emission were set and measured at 540nm/570nm for 
DiL labeled exosomes and exoAA, and 358nm/461nm or 490nm/520nm or 640nm/670nm for 
ER Tracker Blue-White DPX, LysoTracker Green DND-26, and MitoTracker Deep Red, 
respectively.  
Statistical Analysis 
For the all experiments, data are presented as the mean ± SEM. Tests for significant 
differences between the groups were performed using a t-test or one-way ANOVA with multiple 
comparisons (Fisher's pairwise comparisons) using GraphPad Prism 5.0 (GraphPad software, 
San Diego, CA, USA). A minimum p-value of 0.05 was chosen as the significance level. 
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RESULTS 
Drug Release and Stability of Exosomes Loaded with Paclitaxel 
The release of PTX from exosomes loaded with PTX by sonication was evaluated by 
HPLC by placing exoPTX in dialysis membranes with a cut-off of 300 kDa under sink 
conditions and measuring PTX content inside the dialysis tube at varying timepoints (Figure 
2.1A).  ExoPTX showed burst release within the first one hour, and then displayed a sustained 
release profile thereafter.  
Next, the aggregation stability of exosomes in an aqueous solution was assessed at three 
temperatures: 4°C, RT, and 37°C. The size of exosomes was not altered over a period of one 
month at all temperatures tested (Figure 2.1B).  This provides a clinical link for exosomal drug  
Figure 2.1 Characteristics of exosomal PTX formulation. (A) A release profile of exoPTX formulation obtained 
by sonication. (B) Exosomes released from Raw 264.7 macrophages were loaded with PTX as described in the 
materials and methods section, and the size of nanoparticles was measured at 4°C, RT, and 37°C over the course of a 
month. No significant changes in size of the exoPTX were registered at all conditions. 
 
formulations, indicating that multiple lots of exosomal PTX may be prepared and stored prior to 
administration to the patient. 
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Accumulation and Therapeutic Efficacy of exoPTX and exoPTX-AA in Target Cancer 
Cells In Vitro 
The ability to deliver the drug payload into target cells is crucial for the therapeutic 
efficacy of exosomal formulations. First, we studied accumulation levels of fluorescently-labeled 
exosomes in murine Lewis lung carcinoma cells (3LL-M27), and compared them to commonly 
used liposomes or polystyrene (PS) nanoparticles with the same size and level of fluorescence 
(Figure 2.2). These nanocarriers (liposomes and PS nanoparticles) have been utilized in many 
investigations for the delivery of different anticancer agents[141]. 
For this purpose, exosomes were isolated from RAW 264.7 macrophages conditioned 
media, labeled with red fluorescent dye (DIL), and incubated with 3LL-M27 cells for various 
lengths of time. In parallel, liposomes or polystyrene nanoparticles (red, 100 nm) were incubated 
with 3LL-M27 cells for the same duration. Confocal images revealed a profound accumulation of  
 
Figure 2.2 A profound accumulation of exosomes in 3LL-M27 cells in vitro. A: 3LL-M27 cells were incubated 
for 3 or 24 hours with fluorescently-labeled (red) exosomes, or liposomes, or polymer nanoparticles, washed with 
PBS, and the uptake of nanocarriers in cancer cells was visualized by confocal microscopy. The accumulation studies 
(B) confirmed superior uptake of exosomes in 3LL-M27 cancer cells vs. polystyrene nanoparticles. All 
nanoformulations were used at the same fluorescence intensity. Bar: 10 µm. 
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exosomes in cancer cells and limited uptake of liposomes and polystyrene nanoparticles (Figure 
2.2A). Exosomes consist of cellular membranes with numerous adhesive proteins and specific 
vector ligands (e.g. tetraspanins, integrins, LFA1, CD11b and CD18 receptors) on their surface 
[30, 31].  They efficiently adhere to and fuse with target cells to deliver their cargo. The efficient 
uptake of exosomal carriers by cancer cells was further confirmed and quantitated by 
accumulation studies (Figure 2.2 B). The exosomal carriers were taken up about 30 times better 
than synthetic polystyrene nanoparticles. This suggests that PTX loaded into exosomes can be 
delivered to cancer cells in therapeutically sufficient quantities. 
To assess the therapeutic effect of exoPTX, the cytotoxicity of exoPTX  was determined 
in various cancer cell lines using a standard MTT assay [32]. To evaluate the role of drug loading 
into exosomes, a resistant MDR cell line expressing the drug efflux transporter, Pgp 
(MDCKMDR1), and their sensitive counterpart (MDCKWT) were employed in these experiments, 
along with murine 3LL-M27 Lewis Lung Carcinoma cells. 
The incorporation of PTX into exosomes significantly increased its cytotoxicity as 
compared to PTX alone and to the commercially available PTX formulation, Taxol (Table 2.1). 
It is worth noting that the increase in PTX cytotoxicity afforded by exoPTX was greater in Pgp-
overexpressing cells than their sensitive counterparts (MDCKMDR1 and MDCKWT, respectively). 
Thus, the effects of various PTX formulations were expressed in the form of a “Resistance 
Reversion Index” (RRI), i.e. ratio of IC50 of PTX alone, and in nanoformulation 
(IC50PTX/IC50exoPTX, or IC50PTX/IC50taxol). Both PTX formulations caused significant 
sensitization of MDR cells with respect to PTX.  However, the RRI for exoPTX was ten times 
greater than for Taxol. We hypothesized that exoPTX may alter drug intracellular trafficking and 
bypass the drug efflux system more efficiently than Taxol (the increase in cytotoxicity for 
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exoPTX may also be due to the facilitated endosomal release of PTX from exosomes in cancer 
cells). 
 
Table 2.1. Cytotoxicity of different PTX formulations in cancer cells.   The RRI was calculated as IC
50
 of PTX 
vs. IC
50
 of exoPTX or Taxol. 
 
To prove this hypothesis, we examined the accumulation levels of a fluorescent probe 
and Pgp substrate, Dox, incorporated into exosomes (exoDox). Pgp-overexpressing resistant 
MDCKMDR1 cells, and their sensitive counterparts, MDCKWT cells were used in this experiment. 
First, to characterize these cancer cells, elevated Pgp expression levels in MDCKMDR1 cells, and 
low, if any, Pgp levels in MDCKWT cells were confirmed by western blot (Figure 2.3A). Next, 
the uptake of free Dox and the exosome-incorporated drug, exoDox, was compared in the 
presence/absence of Pgp inhibitor, verapamil (Figure 2.3B). As expected, the incorporation of 
Dox into exosomes significantly increased drug accumulation levels in both sensitive and 
resistant cancer cells. Inhibition of Pgp-mediated drug efflux by verapamil elevated 
accumulation levels of free Dox in MDR cells, and did not alter drug accumulation in their 
sensitive counterparts. Interestingly, pre-treatment with verapamil did not significantly increase 
exoDox accumulation levels in resistant MDCKMDR1 cancer cells, indicating that the 
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incorporation of drug into exosomes allowed it to bypass this resistance mechanism (Figure 
2.3B). 
 
Figure 2.3. Effect of Pgp inhibition on Dox accumulation in resistant and sensitive cancer cells.  MDCK
MDR1
 and 
MDCK
WT
 cells grown on 24-well plates were incubated with free Dox or exoDox formulations for two hours, washed, 
and the levels of fluorescence were analyzed in cell lysates.  The incorporation of the drug into exosomes significantly 
increased accumulation of Dox in sensitive and resistant cancer cells. No significant difference between exoDox 
accumulation with or without verapamil was found. Values are means ± SEM (n = 4). Symbols indicate the relative 
level of significance compared with free Dox or Dox in exosomes. 
 
We demonstrated earlier that the incorporation of Pgp substrates, such as R123 or Dox, 
into block-copolymer-based nanocarriers, i.e. Pluronic micelles, increased drug accumulation in 
resistant cancer cells. The mechanism of Pluronic effects is related to the inhibition of the Pgp 
drug efflux transporter by polymer chains incorporated into the membranes of resistant cancer 
cells 22, 33-35[142-145].  To exclude the possibility that exosomes may inhibit Pgp-mediated 
efflux by their fusion with cellular membranes, accumulation of R123 in both resistant and 
sensitive MDCK cancer cells was assessed. For this purpose, MDCKWT and MDCKMDR1 cell 
monolayers were pretreated with a Pgp inhibitor, verapamil (positive control), or empty 
exosomes, or media (negative control), and then were treated with R123 solutions for two hours 
(Figure 2.4).  (R123 does not incorporate into exosomes upon incubation at RT, as was 
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Figure 2.4  Exosomes do not inhibit Pgp-mediated drug efflux in resistant cancer cells.  Resistant MDCK
MDR1
 
cells and their sensitive counterparts MDCK
WT 
were pretreated with verapamil, a well-known Pgp inhibitor, or empty 
exosomes, or media as a control. Then, cells were supplemented with R123 solutions for two hours, washed, and 
accumulation of a Pgp substrate, R123, was examined by fluorescence. Verapamil significantly increased R123 
accumulation in resistant cancer cells and did not alter the R123 uptake in sensitive MDCK
WT
 cells. Contrary to 
verapamil, exosomes pretreatment did not affect accumulation levels of R123in resistant MDCK
MDR1
 cells, indicating 
that exosomes themselves did not inhibit Pgp efflux mechanism. Values are means ± SEM (n = 6). Symbols indicate 
the relative level of significance compared with R123 uptake in verapamil or exosome-free media. 
 
confirmed in preliminary studies (Figure 2.5)).  
R123 accumulation levels in resistant MDCKMDR1 cells were increased almost five times 
in verapamil pre-treated cells. In contrast, pre-treatment with empty exosomes did not affect 
R123 accumulation in MDCKMDR1 cells. As expected, neither pre-treatment with verapamil, nor 
with empty exosomes, altered R123 accumulation levels in sensitive MDCKWT cells. This 
indicates that exosomes themselves do not appear to have any inhibitory effect on Pgp-mediated 
drug efflux;, rather, we hypothesize that they allow incorporated drugs to bypass the Pgp efflux  
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Figure 2.5 R123 does not incorporate into exosomes upon incubation at RT. Exosomes (10
11
 particles/ml) were 
supplemented with R123 solution and incubated at RT as described in the Materials and methods section. Non-
incorporated R123 was separated on from exosomes by size exclusion chromatography using a NAP-10 Sephadex 
G25 column. Fractions were collected from a column and analyzed by fluorescence (for R123) and NTA (for 
exosomes).  The chromatography profile showed two separated peaks; the free R123 was eluted from the column at a 
much later time than the exosomes. 
 
protein through endocytosis-mediated transport and/or fusion with plasma membranes. 
Vectorized Exosomes Are Targeted to Cells Expressing Sigma Receptor 
The ability to delivery a drug payload specifically to target cancer cells while avoiding 
normal healthy cells is essential in achieving therapeutic efficacy as well as minimizing side 
effects.  To this end, the ability of exosomes vectorized to the sigma receptor to target and be 
taken up by cells expressing the sigma receptor was assessed by a receptor competitive inhibition 
study (Figure 2.6).  Exosomes were isolated from RAW 264.7 macrophages conditioned media, 
labeled with a fluorscent dye (DiL), and vectorized to the sigma receptor with DSPE-PEG-AA to 
produce vectorized exosomes (exoAA).  Cells were pre-treated with varying concentrations of 
anisamide (AA) for 30min. and then incubated with fluorescently labeled exoAA with varying 
concentrations of AA for 1h.  Protein content was determined by BCA assay and fluorescence 
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was measured and compared against a known standard to determine the number of exoAA per 
µg protein and the number of exoAA per µg protein was plotted against the concentration of AA.    
Results showed a dose-dependent response to competitive inhibition by AA, indicating that 
vectorized exosomes are targeted to and taken up by cells expressing sigma receptor, and that 
vectorized exosomes are taken by cells via receptor-mediated endocytosis. 
 
Figure 2.6 Receptor Competitive Inhibition Study.  Fluorescently labeled exosomes were incubated with varying 
concentrations of anisamide (AA) and added to 3LL-M27 cells.  After 1h, fluorescence levels were measured and 
normalized to µg protein.  Results show a dose-dependent response to competitive inhibition by AA. 
 
Effect of Proteinase K Treatment on Exosome Uptake 
To explore the role of exosomal surface proteins in exosome uptake, exosomes were 
isolated from RAW 264.7 macrophage conditioned media, labelled with DiL dye, treated with 
proteinase K (or PBS as a control) to digest the exosomal surface proteins, and incubated with 
3LL-M27 cells for varying lengths of time.  Afterwards, fluorescence levels were measured and 
the amount of exosomes/μg protein was quantified (Figure 2.7).   
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Figure 2.7  Exosome Uptake with/without Proteinase K Treatment.  Naïve exosomes or empty sonicated 
exosomes with or without treatment by Proteinase K to digest exosomal surface proteins, such as LFA1, important 
in adhesion and uptake to target cancerous and inflamed cells, were evaluated for their uptake into 3LL-M27 cells.  
Results showed that Proteinase K treatment (exoCLEAVE and exoSONIC-CLEAVE) significantly decreased 
exosome uptake, highlighting the importance of exosomal surface proteins in cell adhesion and uptake. 
 
Results showed that, for both naïve exosomes and sonicated exosomes, digestion of 
exosomal surface proteins by Proteinase K resulted in a decrease of exosome uptake by target 
3LL-M27 cells.  This finding highlights the importance and role of exosomal surface proteins in 
exosome uptake. 
Intracellular Distribution of Exosomes  
Exosomes are known to function as intracellular messengers, delivering proteins and 
nucleic acids[4] from cell to cell.  However, the fate of their cargo remains unknown.  Thus, we 
explored the intracellular fate of exosomes in murine Lewis Lung Carcinoma cells (3LL-M27).  
The fate of both naïve exosomes as well as exoAA targeted to the sigma receptor were assessed.  
For this purpose, exosomes were isolated with RAW 264.7 macrophages conditioned media, 
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labeled with red fluorescent dye (DiL), and vectorized to the sigma receptor as needed as 
described above.   
 
Figure 2.8 Intracellular Distribution of Exosomes.  Fluorescently labeled (DiL, red) exosomes (A, B) or vectorized 
exosomes (C, D) were incubated with 3LL-M27 cells for 1h.  Afterwards, cells were washed and stained with ER 
Tracker (A, C), LysoTracker (B), or MitoTracker (D), shown in green.  Areas of colocalization are shown in yellow.     
 
Exosomes or exoAA were then incubated with 3LL-M27 cells for various lengths of 
time, followed by staining of the mitochondria, lysosomes, or endoplasmic reticulum (ER).  
Confocal images revealed that both exosomes and exoAA were preferentially distributed to the 
ER (Figure 2.8).  Furthermore, confocal images also revealed that vectorization of exosomes did 
not alter the intracellular distribution pattern of exosomes.   
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DISCUSSION 
PTX is a potent chemotherapeutic used to treat many forms of cancer; however, its 
effectiveness for clinical use is hampered by its low aqueous solubility. In addition, PTX is a 
substrate for the drug efflux transporter, Pgp, which significantly reduces its therapeutic efficacy 
in resistant tumors [146].  There have been significant efforts to formulate PTX into various 
nanoformulations to increase solubility, improve pharmacokinetics, and avoid efflux by Pgp, 
including polymer based nanoparticles and liposomes.  However, these systems possess several 
undesirable properties such as the presence of toxic excipients and/or rapid clearance by the 
RES. 
The aggregation stability of exoPTX formulations is imperative for their use in clinic.  We 
report here that our exoPTX formulation was stable at various conditions (4°C, RT, and 37°C) 
for over a month, which confirms previous reports about the long-term stability [147] of 
exosomes. In addition, exosomes may be lyophilized and reconstituted, while retaining their 
morphology and other characteristics [106].   
Exosomes possess an extraordinary ability to interact with and accumulate in target cancer 
cells.  Confocal microscopy studies indicated that exosomes are taken up in considerably greater 
numbers than liposomes or polystyrene nanoparticles.  Because exosomes are taken up in a 
unique manner, we hypothesized that incorporation of PTX into exosomes may not only increase 
its solubility, but also may allow for overcoming of Pgp mediated resistance to PTX.  To validate 
this hypothesis, we first validated the ability of exosomes to improve drug accumulation and 
overcome Pgp-mediated drug efflux in in vitro studies with a fluorescent probe, Dox, which is 
known to be a Pgp substrate. Incorporation of Dox into exosomes significantly increased Dox 
accumulation in MDR cells as compared to free Dox.  Next, we compared the cytotoxicity of our 
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exoPTX formulation in resistant cancer cells and their sensitive counterparts.  Strikingly, the 
increase in cytotoxicity afforded by the exosome formulation of PTX was more than twenty 
times greater in resistant cells (RRI > 53.33) than sensitive cells (RRI = 18.35). The Taxol 
formulation showed little difference in resistant (RRI = 5.85) and sensitive cancer cells (RRI = 
6.17). This effect may be attributed to the difference in route of internalization of exoPTX as 
compared to Taxol. Exosomes and micelles, such as those found in Taxol, are taken up by 
endocytosis, but exosomes have superior uptake due to the presence of adhesion proteins such as 
tetraspanins, integrins, immunoglobulins, proteoglycans, and lectins [136] which are not found 
on artificial nanoparticles. Furthermore, exosomes consist of cellular membranes that may fuse 
with the plasma and/or endocytic membranes and deliver their cargo, bypassing Pgp-mediated 
efflux. Finally, the obtained data indicated that exosomes themselves did not inhibit Pgp, as 
pretreatment with empty exosomes did not increase accumulation of the Pgp substrate, R123, in 
resistant cancer cells.  
It was suggested that the MDR efflux transporters are likely to contribute to the production of 
drug-loaded exosomes during their biogenesis in resistant cancer cells. Thus, Safaei et al. 
reported that cisplatin-resistant cells release exosomes with 2.6 times higher cisplatin content 
than cisplatin sensitive cells [148].  A study by Yamagishi and co-workers suggests that Pgp may 
be also involved in the increased lysosomal sequestration of accumulated drugs [149]. Pgp 
associated with the endosomal membrane excretes the internalized drug into the endosomal 
lumen, where newly formed exosomes are literally incubated with the drug and become “drug-
loaded” before being released from the cell. The same effect was reported with PTX 
incorporated into exosomes during their biogenesis in Pgp-overexpressing bone marrow 
mesenchymal stromal cells (SR4987) [108]. We hypothesized that exoPTX accumulated in the 
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MDR cancer cells may bypass not only efflux by Pgp transporter located on the plasma 
membrane, but also avoid accumulation in lysosomes and multivesicular bodies of cancer cells, 
and therefore reduce drug elimination and increase its therapeutic efficacy in resistant tumors. 
The intracellular fate of exosomes and their cargo is of paramount importance for drug 
delivery applications, thus, we explored the intracellular fate of exosomes and vectorized 
exosomes targeted to the sigma receptor in target Lewis Lung Carcinoma 3LL-M27 cells.  Both 
exosomes and vectorized exosomes shared a similar fate, with the greatest accumulation in the 
ER, followed by lysosomes and finally the mitochondria. 
This work demonstrates that exosomes are an exceptionally potent carrier for PTX.  We 
developed an efficient method of drug loading into and vectorizing exosomes without 
significantly altering their structure, and we showed that vectorized exosomes loaded with PTX 
efficiently accumulate in cancer cells and produce a potent anticancer effect.  Furthermore, the 
apparent ability of exosomes to circumvent the protective properties of drug efflux by Pgp is an 
exciting finding which implies that exosomes may be valuable in treating drug resistant cancers. 
These findings indicate that an exosomal based formulation of PTX could be a valuable tool in 
the future for anticancer therapy.  This data warrants further evaluation of this formulation in an 
in vivo model of cancer. 
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CHAPTER 3. BIODISTRIBUTION AND THERAPEUTIC EFFICACY OF EXOSOME 
BASED PTX FORMULATIONS IN A MOUSE MODEL OF PULMONARY 
METASTASES4 
OVERVIEW 
Metastatic lung cancer is one of the most common and aggressive forms of cancer, 
typically diagnosed during a relatively late stage in its progression which results in little to no 
chance for a cure.  Stage 4 metastatic lung cancer is one of the greatest threats to public health, 
lung metastases are identified in 30 – 55% of all cancer patients.  As a result, lung cancer is the 
leading of cause of cancer-related deaths in the world, responsible for more deaths than breast, 
colon, and prostate cancers combined[150].  The lungs are the most common site of metastases 
and tumor relapse following treatment of the primary tumor mass.   
Regrettably, efficient and targeted delivery of antineoplastic agents to pulmonary 
metastases poses a significant challenge to the scientific and healthcare communities.  Resection 
is the current standard for metastatic cancer, but because pulmonary metastases are distributed 
throughout the pulmonary parenchyma, their excision is difficult if not impossible. Thus, 
successful treatment of pulmonary metastases demands an innovative approach to the design of 
                                                          
4 Some of this text previously appeared in an article in the journal Nanomedicine.  The original citation is as 
follows: Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells. Myung Soo Kim, 
Matthew J. Haney, Yuling Zhao, Richa Gupta, Zhijian He, Natalia L. Klyachko, Aleksandr Piroyan, Marina Sokolsky, 
Alexander v. Kabanov, and Elena V. Batrakova. Nanomedicine, Nov 13. pii: S1549-9634(15)00202-6. doi: 
10.1016/j.nano.2015.10.012. PMID: 26586551 
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drug delivery systems for this application.  We propose the utilization of exosomes released by 
autologous macrophages for the targeted delivery of paclitaxel to pulmonary metastases.  The 
combination of targeting ability with the long circulation time of exosomal-based drug 
formulations offers a powerful and novel delivery platform for anticancer therapy. 
Herein, we have assessed the in vivo biodistribution and efficacy of exosomes loaded 
with PTX in a murine model of metastatic pulmonary cancer.  The objectives of this study were: 
(i) to assess the ability of exosomes to travel to and delivery their drug payload to pulmonary 
metastases, (ii) to assess the ability of vectorized exosomes to travel to and target pulmonary 
metastases, and (iii) to assess the in vivo therapeutic efficacy of paclitaxel loaded in exosomes in 
a murine model of pulmonary metastases. 
Our results showed that exosomes were able to travel to sites of pulmonary metastases when 
administered intranasally or intravenously, and were also able to deliver their drug payload to 
target cancer cells. Furthermore, exosomes loaded with paclitaxel (exoPTX) showed greater in 
vivo therapeutic efficacy in a murine model of pulmonary metastases as compared to a 
commercially available PTX formulation, Taxol.  Taken together, our results indicate that an 
exosomal based formulation of paclitaxel with targeting moieties represents a promising new 
innovation in anticancer therapy for the treatment of pulmonary metastases and other types of 
metastatic cancers. 
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MATERIALS AND METHODS 
Reagents 
Paclitaxel (PTX) was purchased from LC Laboratories (Woburn, MA, USA).  The stock 
solution was prepared in ethanol (EtOH) at a concentration of 10 mg/mL.  Aliquots were stored 
at -20°C.  Doxorubicin (DOX) was purchased from LC Laboratories (Woburn, MA, USA).  The 
stock solution was prepared in DMSO at a concentration of 2 mg/mL and aliquots were stored at 
4°C.  Working solutions of PTX or DOX were prepared fresh according to experimental design 
by serial dilution in an appropriate medium.  A lipophilic fluorescent dye, 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindo-carbocyanine perchlorate (DIL), was purchased from Invitrogen 
(Carlsbad, CA, USA). A fluorescent duy, 2-decanoyl-1-(O-(11-(4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-propionyl)amino)undecyl)-sn-glycero-3-phosphocholine 
(BODIPY-PC) was purchased from Molecular Probes. Doxorubicin, Rhodamine 123 (R123), 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), and Triton X-100 were obtained from 
Sigma-Aldrich (St. Louis, MO, USA).  Cell culture medium and fetal bovine serum (FBS) were 
purchased from Gibco Life Technologies, Inc. (Grand Island, NY, USA). Culture flasks and 
dishes were from Corning Inc. (Corning, NY, USA).  ExoQuick-TC™ Exosome Precipitation 
Solution was obtained from System Biosciences (Mountain View, CA, USA).  ER Tracker Blue-
White DPX, LysoTracker Green DND-26, and MItoTracker Deep Red were purchased from 
Thermo Fisher (Thermo Fisher Scientific, Waltham, MA, USA). 
Cells 
RAW 264.7 macrophages (purchased from ATCC, Manassas, VA, USA) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) high glucose (Gibco, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 1% 
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penicillin and streptomycin at 37°C and 5% CO2.  Murine Lewis lung carcinoma cell subline 
(3LL-M27), a highly metastatic lung clone, was a generous gift from Dr. L. Pelletier (CHUL, 
Laval University, QC, Canada), and were cultured in DMEM high glucose supplemented with 
10% FBS, 10 mM HEPES, 1% penicillin and streptomycin at 37°C and 5% CO2.   
To utilize exosomes from autologous macrophages, bone marrow derived macrophages 
(BMM) were obtained by differentiation of bone marrow stem cells extracted from murine 
femurs (C57Bl/6 mice) as described in[151]. The cells were then cultured for 10 days in media 
supplemented with 1000 U/mL macrophage colony-stimulating factor (M-CSF, Sigma-Aldrich, 
MO, CAS Number 81627-83-0). The purity of monocyte culture was determined by flow 
cytometry using FACS Calibur (BD Biosciences, San Jose, CA). 
Animals 
The experiments were performed with female C57BL/6 mice (Charles River 
Laboratories, Durham, NC, USA) eight weeks of age in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal 
Experiments of the University of North Carolina at Chapel Hill. The animals were kept five per 
cage with an air filter cover under light- (12-hours light/dark cycle) and temperature-controlled 
(22  1o C) environment. All manipulations with the animals were performed under a sterilized 
laminar hood. Food and water were given ad libitum.   
Exosome Isolation 
For all studies, exosome-depleted media was prepared by ultracentrifugation of fetal 
bovine serum (FBS) at 120,000 x g for 110 min to remove all vesicular content prior to addition 
to media.  Exosomes were harvested from the supernatants of RAW 264.7 cells cultured in 
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exosome-depleted media using the ExoQuick-TC™ Kit (System BioSciences; Mountain View, 
CA, USA).  Briefly, > 90% confluent RAW 264.7 cells were cultured in exosome-depleted 
media for 2 days.  50 mL conditioned cell culture media were centrifuged at 300 x g for 10 min 
(Thermo CL-10 centrifuge with O-G26/1 rotor, Thermo Fisher Scientific, Waltham, MA, USA) 
in order to remove cells and cellular debris.  The supernatant was then taken, filtered with a .22 
µm PES filter, and ExoQuick-TC™ Exosome Precipitation Solution (System Biosciences, 
Mountain View, CA, USA) was added to the filtered supernatant and the mixture was vortexed 
and incubated overnight at 4°C.  After overnight incubation, the mixture was vortexed again and 
subsequently centrifuged at 1500 x g for 30 min. and 5 min. to pellet exosomes.  The supernatant 
was discarded and the exosome pellet was resuspended in PBS.  Freshly-prepared exosomes or 
exosomes stored at -20°C were used for all experiments. 
Drug Loading into Exosomes 
For PTX and DOX loading into exosomes, purified exosomes (~1011 exosomes) were 
first mixed with PTX or DOX in 1 mL PBS.  First, PTX was dissolved in ethanol (EtOH, 10 
mg/ml drug in EtOH stock solution) and added to 1 mL exosomes. DOX stock solution was 
prepared in DMSO (2 mg/mL) and added to 1mL exosomes. The PTX-exosome or DOX-
exosome mixture was then sonicated using a Model 505 Sonic Dismembrator with .25” tip 
(Thermo Fisher Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s 
on/off for three minutes with a two minute cooling period between each cycle.  After sonication, 
PTX-loaded exosomes (exoPTX) or DOX-loaded exosomes (exoDOX) solution was incubated at 
37°C for 60 min to allow for recovery of the exosomal membrane.   
Excess free PTX or DOX was separated from exoPTX or exoDOX, respectively, by size 
exclusion chromatography using a NAP-10 Sephadex G25 column (GE Healthcare, 
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Buckinghamshire, UK) according to the manufacturer’s recommended protocol.  Briefly, 750 µL 
of exoPTX or exoDOX were added to the NAP-10 column and the void volume was discarded.  
250 µL of PBS was then added to the column and allowed to enter the gel bed completely and 
the eluate was discarded.  1.2 mL of PBS was then added to the column and the eluate containing 
purified exoPTX or exoDOX was collected and stored at -20°C. 
Quantification of Drug Loading 
The amount of PTX loaded into exosomes was measured by a high performance liquid 
chromatography (HPLC) method.  Briefly, exoPTX (1010 exosomes/0.1mL) in a microcentrifuge 
tube was placed on a heating block set to 75°C to evaporate solvent.  After all solvent had 
evaporated, an equal volume of acetonitrile was added to the microcentrifuge tube and the 
mixture was vortexed, sonicated, and vortexed again.  The sample was then centrifuged at 13,000 
rpm (Thermo Legend Micro 21, Thermo Fisher Scientific, Waltham, MA, USA) for 10 min.  
Following centrifugation, the supernatant was taken and filtered through a Corning Regenerated 
Cellulose .2 µm syringe filter and transferred into HPLC autosampler vials.  20 µL aliquots were 
injected into the HPLC system (Agilent 1200, Agilent Technologies, Palo Alto, CA, USA).  All 
analyses were performed using a C18 column (Supelco Nucleosil C18, 250 mm x 4.6 mm, 5 µm, 
100 Å, Sigma-Aldrich,) with a mobile phase of H2O:acetonitrile (45:55, v/v) at a flow rate of 1 
mL/min at 30°C.  Absorbance was measured at 227 nm to monitor the elution of PTX.  The area 
under the PTX peak was measured for each sample and compared with known concentration of 
standard.  A calibration curve was constructed by plotting peak area versus concentrations of 
paclitaxel and was found to be linear within the tested concentration range (r2 = .997).  
Exosomal protein content was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher 
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Scientific, Waltham, MA, USA) according to the manufacturer’s recommended protocol. 
Loading capacity is expressed by µg protein of exosomes. 
Synthesis of DSPE-PEG-AA 
The synthesis was carried out according to the published synthetic protocol with little 
adjustment[23]. Briefly, to synthesize the N-(2-bromoethyl)-4-methoxy-benzamide, 4-
methyoxybenzoyl chloride (1g, 5.8 mmol) in 50 mL of pre-warmed benzene was mixed with an 
aqueous solution of 2-bromoethylamine hydrobromide (1.32g, 6.4 mmol). The emulsion was 
shaken and cooled in running water during the dropwise addition of 5% aqueous solution of 
sodium hydroxide. The precipitate was solidified out of the reaction mixture within a few 
minutes to an amorphous mass. The mixture was continued stirred for 1h, after which time the 
solid amide was filtered with suction and washed once with benzene and air dry for 2-3h. Then, 
the synthesized N-(2-bromoethyl)-4-methoxy-benzamide (100 mg, 0.4 mmol) was reacted with 
DSPE-PEG-NH2 (100 mg, 23.3 µmol) in acetonitrile (5 mL) in the presence of DIPEA (30 uL, 
0.2 mmol) at 65-70 °C for 16h. After evaporating the solvent, 5 mL of methanol was added to 
dissolve the pellet followed by excess ether (50ml) and it was the kept at -80 °C overnight. The 
precipitate was collected after centrifugation and recrystallized twice. The overall yield was 
70%. The products was characterized by NMR and TLC as reported elsewhere[129]. 
Preparation of Exosomes Vectorized to Sigma-receptor 
Vectorized exosomes targeted to sigma receptor using DSPE-PEG-AA (exoAA) and non-
vectorized control exosomes with DSPE-PEG (exoPEG) were prepared as follows: exosomes 
were isolated as previously described and then varying volumes of 10mg/mL DSPE-PEG or 
DSPE-PEG-AA were added to the exosome solution (for exoPEG and exoAA, respectively).  
100μL of 10mg/mL PTX in EtOH was also added to the mixture when preparing exoPTX-AA.  
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The mixture was then sonicated by the same method used by our lab previously [29].  Briefly, 
the mixture was sonicated using a Model 505 Sonic Dismembrator with .25” tip (Thermo Fisher 
Scientific, USA) with the following settings: 20% amplitude, 6 cycles of 30 s on/off.  After 
sonication, the exoAA or exoPEG solution was incubated at 37°C for 60 min to allow for 
recovery of the exosomal membrane.  Excess free DSPE-PEG or DSPE-PEG-AA was separated 
from exoPEG or exoAA, respectively, by size exclusion chromatography using a NAP-10 
column packed with Sepharose 6b (GE Healthcare, Buckinghamshire, UK) according to the 
manufacturer’s recommended protocol.  Briefly, 750 µL of exoPEG or exoAA were added to the 
NAP-10 column packed with Sephadex 6b and the void volume was discarded.  250 µL of PBS 
was then added to the column and allowed to enter the gel bed completely.  1.2 mL of PBS was 
then added to the column and the eluate containing purified exoPEG or exoAA was collected and 
stored at -20°C. 
Biodistribution of Airway Delivered Exosomes in Mice with Pulmonary Metastases 
C57BL/6 mice (n = 4) were injected intra tail vein (i.v.) with 8FlmC-FLuc-3LL-M27 
cells (5x106 cells/mouse in 100 µl saline) and tumor lung metastases were allowed to establish 
for 10-12 days. In parallel, exosomes isolated from autologous macrophages conditioned media 
were stained with a fluorescent lipophilic dye DiD as described above. Twelve days following 
cancer cells i.v. injection, DiD-labeled exosomes were administered intranasally (i.n., 107 
particles/10µl x 2) to mice with lung metastases. Four hours later, mice were sacrificed and 
perfused according to a standard protocol. Lungs were extracted and sectioned on a microtome at 
a thickness of 20 μm; nuclei were stained with DAPI (300 mM, 5 min). The images of lung 
sections were examined by a confocal fluorescence microscopic system ACAS-570 and 
corresponding filter set, and processed using ImageJ software.  
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Colocalization of Drug Delivered via Exosomes with Pulmonary Metastases 
C57BL/6 mice (n = 4) were injected intra tail vein (i.v.) with GBM8FlmC-3LL-M27 cells 
(5x106 cells/mouse in 100 µl saline) and tumor lung metastases were allowed to establish for 10-
12 days. In parallel, exosomes isolated from autologous macrophages conditioned media were 
loaded with Dox as described above.  Twelve days following cancer cells i.v. injection, mice with 
metastases were injected i.n. with non-labeled exosomes loaded with Dox by sonication as 
described above (107 particles/10µl x 2). Four hours later mice were sacrificed, perfused; lungs 
were extracted, sectioned, and co-localization of Dox with pulmonary metastases was visualized 
by confocal microscopy.  
Biodistribution of Intravenously Injected Vectorized Exosomes in Mice with Pulmonary 
Metastases 
C57BL/6 mice (n = 4) were injected intra tail vein (i.v.) with GFP/3LL-M27 cells (2x106 
cells/mouse in 100 µl saline) and tumor lung metastases were allowed to establish for 10-12 
days. In parallel, exosomes isolated from autologous macrophages conditioned media were 
stained with a fluorescent lipophilic dye DiD and vectorized to the sigma receptor as described 
above. Twelve days following cancer cells i.v. injection, DiD-labeled exosomes were 
administered i.v. (108 particles/100µl) to mice with lung metastases. Four hours later, mice were 
sacrificed and perfused according to a standard protocol. Lungs were extracted and sectioned on 
a microtome at a thickness of 20 μm; nuclei were stained with DAPI (300 mM, 5 min). The 
images of lung sections were examined by a confocal fluorescence microscopic system ACAS-
570 and corresponding filter set.  
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Therapeutic Efficacy of exoPTX Against Pulmonary Metastases 
The antineoplastic effects of exoPTX were evaluated in a mouse model of pulmonary 
metastases. For this purpose, C57BL/6 mice were i.v. injected with 8FlmC-FLuc-3LL-M27 
cancer cells (5x106 cells/100 µl/ mouse). Forty eight hours later, mice were treated i.n. with 
exoPTX (107 particles/10 µl x 2), or Taxol (50 mg/kg/mouse), or saline as a control (n = 7)10 
times every other day. Tumor progression was monitored by luminescence using IVIS system. 
To reduce fluorescence quenching by fur and autofluorescence from solid diet, C57Bl/6 mice 
were shaved and kept on liquid diet for 48 hours prior to the imaging studies. For background 
fluorescence level evaluation, all animals were imaged before the injections in the IVIS 200 
Series imaging system (Caliper, Xenogen Co., Life Sciences). The animals were imaged at 
various time points (1 – 22 days) post-treatment as described [152]. The chemoluminescent 
signal was quantified by Living Image® 2.50 software. To assess amount of cancer metastases at 
day 21, mice were sacrificed, perfused, and lung slides obtained on microtome (Thermo 
Scientific) were examined by confocal microscopy.  
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RESULTS 
Co-localization of Airway-delivered Exosomes with Pulmonary Metastases in Lewis Lung 
Carcinoma (LLC) mouse model 
To establish an in vivo model of pulmonary metastases, C57BL/6 mice were injected 
intra-tail vein (5x106 cells/100 µL) with 3LL-M27 cells.  Twenty days later, mice were 
sacrificed, perfused, and lungs were isolated, sectioned, and stained with Hematoxylin and Eosin 
(H&E). Multiple metastases were detected in whole lungs (Figure 3.1A). Histological 
evaluations revealed that the structure of alveoli in tumor-bearing lungs was disrupted by tumor 
cells (Figure 3.1B).  
 
Figure 3.1.  Lung metastasis model of Lewis Lung Carcinoma (3LL-M27). C57BL/6 mice were i.v. injected with 
3LL/M27 cells. 21 days following the injection, multiple metastases (arrows) were detected on gross images of 
tumor-bearing lungs (A), and lung sections (B).  
 
To visualize the ability of exosomes to target and deliver their payload to cancer 
metastases, confocal imaging studies were conducted in an LLC mouse model. 3LL-M27 cells 
were transduced with lentiviral vectors encoding the optical reporter mCherry (8FlmC) 
fluorescent protein and Luciferase (Luc). To induce metastases, C57BL/6 mice were injected 
with 8FlmC-FLuc-3LL-M27 (red, Figure 3.2A) intra-tail vein as described in the Materials and 
Methods section. 22 days later, autologous exosomes stained with a fluorescent dye, DiD 
B A 
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(green), were administered intranasally (i.n., 107 particles/10µl) to C57BL/6 mice (Figure 3.2B). 
Four hours later, mice were sacrificed, perfused; lungs were sectioned on microtome and 
examined by confocal microscopy. Nuclei were stained with DAPI (blue, Figure 3.2C). 
Confocal images revealed 97.9± 2.0% of exosomes (Figure 3.2D) were co-localized with lung 
metastases, indicating efficient targeting of exoPTX in vivo.  
 
Figure 3.2. Co-localization of airway-delivered exosomes with pulmonary metastases. Exosomes were isolated 
from macrophages conditioned media, and labeled with fluorescent dye, DiD (green).  C57BL/6 mice were i.v. injected 
with 8FlmC-FLuc-3LL-M27 (red). 22 days later, the mice with established pulmonary metastases (red) were i.n. 
injected with DiD-labeled exosomes (green). 4 hours later, mice were euthanized, perfused, lungs were sectioned, and 
stained with DAPI (blue). The confocal images revealed near complete co-localization of exosomes with metastases 
(yellow). Bar: 50 µm. 
 
A similar experiment was performed with exoDox formulation in order to visualize drug 
delivery to pulmonary metastases (Figure 3.3). Non-labeled exosomes loaded with Dox (green, 
Exosomes 3LL-M27 
C 
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D 
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Figure 3.3B) were i.n. administered to mice with established 8FlmC-FLuc-3LL-M27 metastases 
(red, Figure 3.3A). Four hours later, mice were euthanized, perfused, and lung sections were 
taken and stained with the nuclei marker DAPI (blue). Confocal images revealed a substantial 
amount of Dox in the lungs co-localized with cancer cells (yellow, Figure 3.3C). These results 
indicate that airway-administered exosomes reached pulmonary metastases and delivered their 
drug payload to target cancer cells.  
 
Figure 3.3. Co-localization of airway-delivered exoDox with pulmonary metastases. Exosomes were isolated from 
macrophages conditioned media, and loaded woth Dox (green).  C57BL/6 mice were i.v. injected with 3LL-M27 cells 
transduced with lentiviral vectors encoding the optical reporter mCherry (8FlmC) fluorescent protein (red, A). 21 days 
later, the mice with established pulmonary metastases (red) were i.n. injected with DID-labeled exosomes (B, green). 
4 hours later, mice were euthanized, perfused, lungs were sectioned, and stained with DAPI (blue). The confocal 
images revealed a significant co-localization of exosome-delivered Dox with metastases (yellow, C). Bar: 20 µm. 
 
Co-localization of Intravenously-delivered Vectorized Exosomes with Pulmonary 
Metastases in Lewis Lung Carcinoma (LLC) mouse model  
In order to assess the ability of vectorized exosomes to target sigma receptor expressing 
pulmonary metastases, confocal images were conducted in an LLC mouse model.  3LL-M27 
cells were transduced with lentiviral vectors encoding the optical reporter GFP fluorescent 
protein.  To induce metastases, C57BL/6 mice were injected with GFP/3LL-M27 intra-tail vein 
as described in the Materials and Methods section.  7 days later, autologous non-vectorized (Fig. 
A C B 
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3.4.A-C) and vectorized exosomes (Fig. 3.4.D-F) stained with a fluorescent dye, DiD (red), were 
administered intravenously (107 particles/10µl) to C57BL/6 mice.  Four hours later, mice were 
sacrificed, perfused; lungs were sectioned on microtome and examined by confocal microscopy.  
 
Figure 3.4. Co-localization of intravenously-delivered vectorized exosomes with pulmonary metastases. 
Exosomes were isolated from macrophages conditioned media, and labelled with DiD dye (red, A, D).  C57BL/6 mice 
were i.v. injected with 3LL-M27 cells transduced with lentiviral vectors encoding the optical reporter GFP fluorescent 
protein (green, B, E). 7 days later, the mice with established pulmonary metastases (green) were i.v. injected with 
DiD-labeled exosomes (red, A) or vectorized exosomes (red, D). 4 hours later, mice were euthanized, perfused, lungs 
were sectioned, and stained with DAPI (blue). The confocal images revealed a significant co-localization of vectorized 
exosomes with metastases (94.4 + 0.8%) and minimal colocalization of non-vectorized exosomes with metastases 
(21.8 + 0.2% ) (yellow, F). Bar: 20 µm. 
Nuclei were stained with DAPI.  Confocal images revealed a minimal amount of non-vectorized 
exosomes were colocalized with lung metastases (21.8 + 0.2%) whereas a substantial amount of 
vectorized exosomes were co-localized with lung metastases (94.4 + 0.8% ) (yellow, Figure 
3.4C), indicating efficient in vivo targeting of vectorized exosomes when administered i.v.   
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Noteworthy, vectorized exosomes showed a few, if any, colocalization with healthy cells 
in the lungs of control healthy mice (Figure 3.5C), suggesting that vectorized exosomes might 
have minimal off-target effects. 
 
Figure 3.5. Intravenously-delivered vectorized exosomes do not colocalize with healthy lung cells. Exosomes 
were isolated from macrophages conditioned media, and labelled with DiD dye (red, A).  Healthy C57BL/6 mice were 
i.v. injected with DiD-labeled vectorized exosomes (red, A). 4 hours later, mice were euthanized, perfused, lungs were 
sectioned, and stained with DAPI (blue). The confocal images revealed no co-localization of vectorized exosomes 
with healthy lung cells (yellow, C). Bar: 20 µm. 
 
Therapeutic Efficacy of exoPTX Against Pulmonary Metastases 
To provide insight into the potential of exosome-based therapeutic delivery, the 
antineoplastic effects of exoPTX were evaluated in an LLC mouse model of pulmonary 
metastases. This model is particularly relevant to the present investigation, as it was 
demonstrated that 3LL-M27 tumor cells have high expression levels of the MDR1 gene and Pgp 
expression in vivo [153].  
Exosomes/DAPI 3LL-M27/DAPI Superposition of all 
A C B 
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For this purpose, C57BL/6 mice were i.v. injected with 8FlmC-FLuc-3LL-M27 cells as 
described in the Materials and Methods section. 48 hours later, mice were i.n. administered 
exoPTX (107 particles/10 µl x 2,), or Taxol, or saline as a control ten times every other day.  
Figure 3.6. Inhibition of metastases growth in mouse lungs upon exoPTX treatment. C57Bl/6 mice were i.v. 
injected with 8FlmC-FLuc-3LL-M27 (red) cells to establish pulmonary metastases. 48 hour later mice were treated 
with exoPTX, or Taxol, or saline as a control, and the treatment was repeated every other day for a total of ten 
treatments. Representative IVIS images from each group were taken at day 22 (A). Statistical significance of 
metastases luminescence levels from IVIS images in lungs of treated animals compared to control mice injected 
with saline is shown by asterisk (*p < 0.05; **p < 0.005), calculated by one-way ANOVA (B). Errors are mean ± 
SEM, N = 7. Symbols indicate the relative level of significance compared with control mice treated with saline. At 
the endpoint, mice were sacrificed, perfused, and lung slides were examined by confocal microscopy (C). Bar: 10 
µm.  
 
Progression of pulmonary metastases in treated mice was monitored by IVIS by 
observing the luminescence of transduced cancer cells.  Representative fluorescent and light 
images of dorsal planes of the injected animals at day 22 are shown on (Figure 3.4A). A 
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significant (p < 0.05) inhibition in the metastases growth by exoPTX treatment was 
demonstrated (Figure 3.4B).  Taxol treatment was shown to inhibit metastases growth as 
compared to non-treated controls (saline), although to a lesser extent than exoPTX treatment. 
We further examined the anti-tumor efficacy of PTX formulations on pulmonary 
metastases growth by confocal microscopy. C57BL/6 mice with established 8FlmC-FLuc-3LL-
M27 pulmonary metastases were treated with exoPTX, Taxol or saline as described above. At the 
end point of the experiment (day 22), the mice were sacrificed, perfused, and lungs were 
sectioned on microtome. The lung sections were visualized using confocal microscopy. A 
marked number of fluorescent transduced cancer cells (red) were detected in the lungs of animals 
treated with Taxol (Figure 3.6C), while only a few cancer cells were observed in the lungs of 
exoPTX treated animals. This suggests the superior antineoplastic efficacy of our exosomal PTX 
formulation as compared to Taxol (Figure 3.6C).  
Altogether, our exoPTX formulation showed potent inhibition of pulmonary metastases 
growth in mice and represents a novel and promising strategy for the treatment of drug resistant 
cancers.  
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DISCUSSION 
Using exosomes as drug delivery vehicles takes advantage of their natural carriage and 
extraordinary ability to interact with target cells. It offers several benefits over common drug 
administration regimens. Herein, the therapeutic efficacy of exoPTX formulation against 
pulmonary metastases was demonstrated in an LLC mouse model. Intriguingly, airway-
delivered exosomes showed near complete co-localization with cancer metastases in this 
model. We hypothesized that macrophage-released exosomes have specific proteins located 
on their surface which allows for their preferential accumulation in cancer cells. It is known 
that exosome-mediated cell-to-cell communication is the key in the battle between cancer 
and the immune system [49]. Furthermore, Parolini et al. [50] showed that exosome fusion 
with target cells occurs more efficiently under acidic conditions, implying that exosomes 
may be taken up preferentially by tumors (which have an acidic microenvironment) rather 
than the surrounding healthy tissue.  Further investigations are necessary to uncover this 
mechanism. Our results show that exoPTX demonstrated superior inhibition of pulmonary 
metastases growth in LLC mouse model. All three mechanisms mentioned here are likely to 
have significant impact on exoPTX anticancer activity, i.e.: (i) preferential accumulation in 
cancer cells, (ii) efficient delivery of incorporated cargo into target cancer cells, and (iii) 
overcoming of Pgp-mediated drug efflux in resistant cancer cells. 
Drug-loaded exosomes may well serve as a next generation drug delivery mechanism that 
combines nanoparticle size with non-cytotoxic effects, a high drug carrying capacity, and a 
low immunogenic profile. Further tailoring exosomes can provide biologically-active carriers 
that may be modified in accordance to the disease and produce cytotoxic (for cancer 
treatment) or neuroprotective (for the treatment of neurodegenerative disorders) effects, 
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enhancing the therapeutic outcomes. Indeed, some technological, functional and safety 
features of exosomal-based drug formulations are still to be addressed. A deficiency in our 
knowledge of the molecular mechanisms of exosomes formation, and lack of methods to 
interfere with the packaging of cargo or with vesicle release still hampers identification of 
their physiological relevance in vivo. Certainly, the complexity of these therapeutic 
interventions is challenging, yet they promise an unparalleled efficacy in the treatment of 
many life-threatening conditions, including those lacking effective pharmacotherapy.  
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